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ABSTRACT 
 
Giardia lamblia is a common intestinal protozoan parasite, causing the gut infection 
giardiasis. In humans, the infection may vary from asymptomatic carrier stage to a more 
severe malabsorption syndrome or chronic sequelae. The first line treatment in Norway is 
metronidazole (MTZ). Recently, MTZ-refractory cases of giardiasis have increased. The 
mechanism of MTZ-resistance in Giardia is not well understood.  
 
This study examined the flavohemoglobin (FlHb) from the two human-infective Giardia 
assemblages (A and B). FlHb is an enzyme thought to play a major role in nitric oxide (NO) 
detoxification in Giardia. In addition to FlHb, the enzymes nitroreductase 1 (NR1) and 
nitroreductase 2 (NR2) from assemblage B, which are thought to activate and inactivate MTZ 
respectively, and also be involved in MTZ resistance, were examined.  
 
FlHb from assemblage A was expressed using E.coli as host cells, and purified using the Ni-
NTA affinity purification system, followed by size exclusion chromatography (SEC). 
Structural characterization and stability tests including circular dichroism (CD), thermofluor, 
light scattering (LS), small angle X-ray scattering (SAXS) were performed for FlHb from 
assemblage A. In addition, screening for crystallization conditions was done to get crystals for 
crystallographic studies. NR1 and FlHb from assemblage B were cloned and expressed using 
E.coli as host cells, and initial purification trials were done, but time did not allow further 
research of these. NR2 was not straightforward to clone, and the time limit put an end for 
further attempts.  
 
From our results, it was observed that FlHb from assemblage A separated into two different 
variants during SEC. One of the variants containing heme, and one variant without heme. 
Comparison from structural characterization suggested that the heme-less variant has a more 
open structural shape and behaved like a dimer. The heme-containing variant, which is the 
active variant of interest, is monomeric and has a closed, more globular shape.  
 
In conclusion, further research needs to be performed and crystals need to be obtained for 
NR1, NR2 and FlHb in order to obtain more information about the protein functions and to 
better understand their role in MTZ resistance in Giardia.   
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1. INTRODUCTION 
 
1.1 The parasite Giardia lamblia 
1.1.1 Epidemiology 
Giardia lamblia (also known as Giardia duodenalis and Giardia intestinalis, from now on 
Giardia) belongs to a group of binucleate organisms named diplomonads (1, 2). It is the most 
common intestinal protozoan parasite infecting humans in both developing (3) and developed 
countries (4). Due to poor hygiene and sanitation, infection with Giardia, giardiasis, is more 
prevalent in developing countries, where children often are affected. It has been reported that 
approximately 15 % of children aged 0-24 months in the developing world are infected (5). 
Giardiasis is further a contribution to the global problem of enteric infections, which is one of 
the most important causes of morbidity, mortality and poor linear growth in children under 5 
years old (6, 7). Annually, Giardia is responsible for up to 280 million infections worldwide 
(8).  
 
In Norway and other developed countries, giardiasis is mainly considered to be an imported 
disease (9). In the autumn of 2004, a large outbreak of giardiasis occurred in Bergen, Norway. 
The outbreak was caused by Giardia assemblage B (10), and roughly 1500 people had 
laboratory confirmed giardiasis (11, 12). Some patients did not respond to metronidazole 
(MTZ) treatment but were cured with second and third line alternatives. (13). For some 
people, the infection gave long-term consequences even though they received treatment. 
Many of the persons exposed to giardiasis during the outbreak, later reported chronic sequelae 
like irritable bowel syndrome (IBS), chronic fatigue (CF) and food intolerance (14, 15).  
 
1.1.2 Biology of Giardia 
Antony van Leeuwenhoek was the first to observe and describe the Giardia parasite in 1681. 
It was later named after the French zoologist Alfred Mathieu Giard (16). Giardia is a 
microaerophilic eukaryotic protozoan parasite (17). It is thought to be one of the most 
primitive extant eukaryotic organism and it is missing mitochondria, nucleoli and 
peroxisomes (1). 
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Giardia has two major stages in its life cycle; the trophozoite and the cyst. The trophozoite 
has a pear-shape, containing two nuclei, cytoskeleton made of microtubules and microtubule-
associated proteins that assemble in structures such as the adhesive disc, the median body, the 
funis and four pair of flagella. By light microscopy, Giardia looks like a smiling face, where 
the eyes are the two nuclei and the mouth is the median body line (8). The structure of the 
trophozoite and the cyst and their components are presented in Figure 1.1. 
 
The size of the trophozoite measures 12-15 µm in length and 5-9 µm in width. The cyst is 
about the same size (18). The cyst is the robust form, where the cyst wall and an inner layer 
consist of two membranes protecting the organism. The adhesive disc and flagella are here 
dissembled and stored inside. The cyst has four tetraploid nuclei (18). 
 
Giardia is lacking mitochondria, but a different mitochondrial remnant organelle, the 
mitosome, has some of the same functions. The mitosome is suggested to be involved in the 
synthesis of iron-sulfur (Fe-S) clusters (19). Fe-S clusters are thought to play important roles 
in the reduction and oxidation reactions of mitochondrial electron transport, energy 
metabolism, regulation of gene expression and a number of metabolic pathways (20).  
 
 
Figure 1.1:  Structure of the Giardia trophozoite and cyst. The trophozoite is on the left hand side and the cyst is 
on the right hand side. The flagella are organized in four pairs. AF (anterior flagella), PLF (posterior/lateral 
flagella), CF (caudal flagella) and VF (ventral flagella). Figure taken from Ankarklev et. al (18).  
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1.1.3 Assemblages of Giardia 
Initially, Giardia was divided into species based on the host from which the organism was 
obtained. Later, it was observed that the Giardia spp. from different hosts were morphological 
identical (1). According to this observation, three species were named (Giardia agilis, 
Giardia labmlia and Giardia muris) on the basis of morphological differences detected by 
light microscopy (1). Further advances in technology have provided new tools, new 
techniques such as molecular and electron micrographic have been used to classify Giardia 
spp. In recent times, reclassification and new species can be done by sequence comparison of 
the small-subunit ribosomal RNA (2). Eight assemblages (A-H) of G. lamblia have been 
identified whereas assemblage A and B infects humans (21, 22). Assemblages are further 
divided into smaller subdivisions, based on several factors, including comparison of 
electrophoretic mobility of enzymes and chromosomes, and sequencing of genes (22).  
 
1.1.4 The life cycle of Giardia 
The life cycle consist of two main processes: excystation (cyst to trophozoite) and encystation 
(trophozoite to cyst). Outside the host, the parasite is encapsulated in a cyst wall that protects 
it from hypotonic lysis in the environment (18). In the cyst, the parasite metabolism is 
downregulated (23). After entering the stomach of the host, stomach acid triggers excystation, 
resulting in the trophozoite. The trophozoite is the disease-causing stage of the life cycle of 
Giardia. In this stage, the parasite has high mobility because of the flagella and is able to 
attach strongly to the enterocytes found in the upper small intestine of the host, with its 
adhesive disc (2). The life cycle is shown in Figure 1.2.  
 
Encystation is the opposite process. This process transforms the trophozoites into the infective 
cyst. Encystation is triggered by host-specific factors such as high levels of bile, low levels of 
cholesterol and a basic pH (24). The trophozoite is gradually changing into a cyst by loosing 
its flagella, building the cyst wall and downregulate its metabolism (18, 23). The cysts will 
then pass through the last part of the colon and are shed in the feces and may infect other 
hosts (18). The infective cysts may survive for months in soil or water, waiting for a new host 
to drink or eat contaminated water or food (25). Giardia cysts may be spread through 
consumption of untreated drinking water or food (25), zoonotic transmission (10), person-to-
person contact, and the infective dose is low (10 cysts or less) (26).  
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Figure 1.2: The life cycle of Giardia lamblia. Humans get infected by cysts from contaminated food/water or 
other humans. The cysts undergo excystation, and become trophozoites. The trophozoites are causing the disease 
giardiasis. They can undergo encystation and become cysts again. Cysts and trophozoites are passed out in the 
stool, but only the cysts can survive outside the host and infect new hosts. Figure taken from Esch et al. (25)  
	  
1.2 The disease giardiasis  
The infection caused by Giardia is named giardiasis. The infection may have two clinical 
outcomes, symptomatic or asymptomatic (27). The symptomatic parasitic infection is 
characterized by watery diarrhea, epigastric pain, nausea, vomiting and weight loss, and the 
clinical effects of the infection may vary from the asymptomatic carrier stage to a more severe 
malabsorption syndrome or chronic sequelae (28, 29). Symptoms usually appear 6-15 days 
after infection.  Often the infection is asymptomatic (27, 30). 
Giardiasis can be divided into two disease phases: acute and chronic. The acute phase is 
usually short-term, characterized by flatulence and abdominal distension with cramps and 
frequent and watery diarrhea. Later the feces becomes bulky, greasy and and the patient may 
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experience offensive odors related to toilet visits (31). The chronic phase is associated with 
malaise, weight loss and stools are usually yellow/pale, frequent and of small volume.  
 
The disease is diagnosed by antigen detection assays, nucleic acid detection assays and stool 
microscopy (32). Today, a sensitive and specific method for the detection is often used to 
diagnose intestinal parasitic infections. The method is real-time PCR, which uses fluorescent 
detection probes (33).  
 
1.2.1 Treatment of giardiasis   
Giardiasis is usually treated with MTZ or other nitroimidazoles (18). MTZ is the first line 
treatment in Norway and many other countries. MTZ has an estimated effect of 60 - 90 % 
(27). In cases where MTZ do not show any effect, or is not recommended (such as during 
pregnancy), other antiparasitic drugs have shown good effect. The drugs that may be used and 
their treatment efficacy are the following: tinidazole (74-100%), quinacrine (92-100%), 
albendazole (24-100%) and furazolidone (80-100%). In cases of pregnancy, promomycin (55-
90%) is recommended (13). When treatment failure occurs, treatment with a combination of 
drugs is recommended. The combination of albendazole (or quinacrine) and MTZ has been 
effective and well tolerated as treatment of MTZ-refractory giardiasis (13). 
 
1.2.2 Metronidazole – the main drug 
 MTZ is listed as an “essential medicine” by WHO (34), and was developed in the late 1950s 
against the microaerophilic parasite, Trichomonas vaginalis. The drug showed to be effective 
and was soon tested against other anaerobic and microaerophilic pathogens, including Giardia 
(35).  
 
MTZ is a 5-nitroimidazole prodrug. To become activated, MTZ, needs to be reduced at its 
nitro group (see Figure 1.3). One reduction mechanism is thought to be caused by electrons 
donated from the enzyme pyruvate flavodoxin/ferredoxin oxidoreductase (PFOR). This 
enzyme transfers electrons from pyruvate to ferredoxin (Fd). The reduced Fd is then 
reoxidized by ferredoxin:NAD oxidoreductase transferring its electrons to NAD(P). Resulting 
in NAD(P)H, which may then transfer its electrons to oxygen (O2). The reaction is catalyzed 
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by NAD(P)H oxidase (36).   
 
Thioredoxin reductase (TrxR) is another enzyme that may activate MTZ using NADPH as an 
electron donor. A third enzyme, has also been showed to be able to activate MTZ, and is 
known as nitroreductase 1 (NR1) (35). NR1 has a Fd domain and it could potentially have a 
similar activating mechanism of MTZ as the PFOR and Fd coupled activation mechanism 
(37). Figure 1.3 illustrates how the enzymes here may activate MTZ.  
 
Nitroimidazoles may capture electrons directly from the reduced Fds or from the NAD(P)H 
oxidase, thus yielding toxic radicals causing irreversible damage in the parasite (38). If O2 is 
present, the active nitro radical form is converted back to the non-toxic parent compound (21). 
Because of this, the drug works only under anaerobic or microaerophilic conditions. The cell 
damaging effects of MTZ include damage of DNA in microaerophiles and anaerobic 
microorganisms by introducing double strand breaks and degradation of elongation factor 1-γ 
(EF1- γ) (important in protein translation) (35).  In addition, MTZ may cause oxidative stress 
by forming adducts with cysteine and inhibits the redox enzyme TrxR (35, 39). Cysteine has 
antioxidant properties and is thought to protect Giardia against oxidative stress (40). In 
addition to activate MTZ, TrxR acts as an antioxidant to protect the parasite against oxidative 
stress (41). MTZ may also be inactivated and detoxified by an enzyme assumed to be 
responsible for inactivation, and is known as nitroreductase 2 (NR2) (35). Figure 1.3 
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Figure 1.3: Activation and inactivation of metronidazole in Giardia. A: Reduction and oxidation of the prodrug 
(MET-NO2) resulting in toxic intermediates and the final inert amine (MET-NH2). B: PFORs role in activation 
of MTZ C: MTZ may react with oxygen and create free radicals. D: Thioredoxin reducatse activates MTZ using 
NADH as electron donor. E: NR1 activates MTZ using NADH as electron donor. F: NR2 inactivates MTZ by 
completely reducing the prodrug to the inert amine, using NADH as electron donor. Figure taken from Ansell et. 
al (37). 
 
1.3 Drug resistance  
	  
Drug resistance in Giardia is complex and far from fully understood. Recently, treatment-
refractory cases of giardiasis have increased and appeared with a high prevalence. In a study 
from the hospital of tropical diseases in London, England, treatment failure increased from 
15.1% in 2008 to 40.2% in 2013 (42). The best described mechanism of resistance is the loss 
of the parasite´s ability to activate 5-nitroimidazole prodrugs to toxic radicals by reduction, 
thus effectively allowing the parasite to avoid suicidal drug activation (17).  
 
MTZ-resistance has been associated with decrease in activity of the enzymes PFOR, Fd and 
NR1, by comparing MTZ-susceptible and laboratory induced MTZ-resistant Giardia lines 
(43-46). Some of the MTZ-resistant Giardia isolates have exhibited lower PFOR expression 
levels, meaning that PFOR may be one of the main targets for 5-nitroimidazole in Giardia 
(47). Evidence has however shown that PFOR may not be the only enzyme capable of 
activating nitro drugs in microaerophilic or anaerobic pathogens (Figure 1.3). Recent studies 
on Giardia clones and MTZ or nitroimidazole resistant strains have revealed that resistance 
may occur without downregulation of PFOR (48, 49). Although some 5-nitroimidazole drugs 
seem to interact directly with PFOR, it is unlikely that Fd directly performs the reduction of 
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the nitro group, as it is more likely that this reaction is catalyzed by NRs (47). It has been 
suggested that loss of either the PFOR/ferredoxin couple or NR1 can lead to MTZ resistance 
(44, 47, 50, 51). Upregulation of NR2 may also result in MTZ resistance (37). Two genes, fdp 
and nadhox which, respectively, encodes for the enzymes flavodiiron protein (FDP) and 
NADH oxidase have recently been found to be upregulated in some albendazole resistant 
clones of the parasite, pointing to a possible linkage between drug resistance and O2 
metabolism in Giardia (21). FDP and NADH oxidase may play a major role in O2 
detoxification (52). In essence, resistance in Giardia probably constitutes several mechanisms 
of both downregulation of MTZ activating enzymes, and upregulation of MTZ inactivating 
enzymes (50). 
 
1.4 Oxidative and nitrosative stress 
	  
Giardia trophozoites are attached to the intestinal mucosa of the host, and will thus be 
exposed to O2 and nitric oxide (NO). NO is produced by the NO-synthases (NOSs) in the 
intestinal epithelial cells and derived from reduction of NO2- to NO (21). It is also produced 
by the immune system in humans to fight microbial pathogens (51). To survive, the parasite 
needs to handle both O2 and NO. Giardia has an antioxidant defense system to protect itself 
(51) from the harmful effects of these two substances (Figure 1.4).  
 
	  
Figure 1.4: O2 and NO are detoxified in Giardia. The cofactor FMN and the enzyme FlHb, NR1 and NR2 with 
their Fds are all involved in detoxification. Figure cropped and taken from Ansell et. al (37). 
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1.4.1 Oxygen detoxification 
NADH oxidases are flavoenzymes, which catalyze the reduction of O2, resulting in the 
production of O2-, H2O2 or H2O. NADH oxidase from Giardia trophozoites have shown to be 
able to convert O2 to H2O without producing partially reduced oxygen; O2-. This enzyme 
uses NADPH or NADH as electron donor (21, 51). Another group of enzymes involved in 
detoxifying O2 are FDPs. The cores of these enzymes contain two redox centers: a flavin 
mononucleotide (FMN) and a non-heme Fe-Fe active site (diiron site). FMN is the electron 
entry site into the enzyme. Electrons derived from NADH are transported through FMN into 
the diiron site and catalyzes the full reduction of O2 to H2O (51).  
 
1.4.2 Nitric oxide detoxification 
One mechanism of NO detoxification is that electrons derived from NADH are transported 
through FMN into the diiron site and catalyze NO to N2O. Giardia codes for a 
flavohemoglobin (FlHb), which is a NO-detoxifying bacterial enzyme acquired through 
lateral transfer from prokaryotic organisms (53). This enzyme is thought to play a major role 
in the NO detoxification in Giardia (51) (see Figure 1.4). FlHb is able to catalyze the 
degradation of NO to NO3- using O2 as a co-substrate (54). Figure 1.4 illustrates this process. 
It also illustrates how FMN with help from NADH converts NO to non-toxic compounds.  
 
1.5 Proteins  
	  
Proteins are biological macromolecules built from amino acid (AA) residues (55). Proteins 
are essential in biological processes. They can function as catalysts, transporters, generate 
movement and control growth and cell differentiation to mention some of the main functions 
(55). The structure of the protein and its functional groups will decide the function of the 
protein. The structure of proteins can be divided into levels of structure; primary, secondary, 
tertiary and quaternary (56). The primary structure is defined as the AA sequence (plus intra- 
and interchain covalent cross-links if any) in the polypeptide chain (56). The polypeptide 
chain is flexible and the primary structure can turn into multiple conformations. The main 
chain conformations are known as the secondary structure. The two main types of secondary 
structures are α-helices and β-sheets (56). The different combinations of α-helices and β-
sheets create the tertiary structure, a three dimensional (3D) structure. In several cases, the 
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proteins contain more than one subunit, and the assembly of the subunits is called the 
quaternary structure (56).   
 
The genetic code of a protein is translated from nucleic acid sequences of genes to the AA 
sequence of the protein. The unit of coding for one AA is a triplet of nucleotides, named a 
codon (56). The unique AA sequence of a protein determines its 3D structure. The function of 
a protein is dependent on its structure, which depends on physical and chemical parameters 
(57). In addition to AA, ions, small organic ligands and water molecules are integral parts of 
several protein structures (56). Studying proteins, their structure, folding and compositions are 
important to understand their function and role in biological processes (57). 
 
1.5.1 Enzymes  
Proteins are classified based on their functions. Enzymes are in most cases proteins (some are 
RNA molecules, ribozymes) (58, 59) that work as biological catalysts (59). Enzymes speed up 
reactions by stabilizing transition states, the highest energy point on a reaction pathway (59). 
Enzymes binds the transitions state more tightly than they bind substrates to altering the 
energy barrier between the substrate and the product (56). They are specific to the substrate 
due to complementary between the enzyme and the substrate, known as the “lock and key” 
model. Another model is “induced fit”, where the enzyme undergoes conformational changes 
upon binding to the substrate (60).  
 
 1.5.2 Flavohemoglobin  
FlHb (also named flavohemoprotein) genes are found in both prokaryotes and eukaryotes and 
they are recognized by a heme pocket inside (61). The FlHb family belongs to the globin 
superfamily. All globins are structurally related to hemoglobins (Hbs) and myoglobins (Mbs) 
with conservation of the heme pocket (62). Even though FlHbs appear in various species, 
sequence alignments show that the FlHb family is a very homogeneous group of proteins 
(62). FlHb consists of a heart shape structure with three different domains, the C-terminal 
NAD-binding, the FAD-binding, and the N-terminal globin domain. The globin domain 
structure has six helices (A-H) with a long H-helix. The D-helix is substituted by a large loop 
region. The loop between the C and E helices (CE loop) in the globin domain forms a distinct 
hydrophilic cavity with a strong electron density (anion binding site). The location of the loop 
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on the heme edge and the strong electron density indicates that it may interact with the FAD 
cofactor (63).   
 
The FAD-binding domain consists of a six-stranded antiparallel β-barrel, a small α-helix 
capping the β-barrel on the bottom, and a long loop connecting β2, β3 β-sheets on the top. 
The loop between β5 and the α-helix is responsible for the different orientations of the 
adenosine molecule in space (61). Figure 1.5 is an example of a FlHb, and illustrates where 
the heme is bound in its pocket, and where FAD is bound.  
 
	  
Figure 1.5: Crystal structure of flavohemoprotein from Alcaligenes eutrophus. The globin domain is colored 
pink, the FAD binding domain is colored blue and the NAD binding domain is colored green. Heme is showed in 
red inside the heme-pocket, and NAD is showed in orange. The figure is created with PyMOL, using pdb-file 
1CQX from RCSB PDB and the article from Erlmer et. Al (64).  
 
The crystal structure of FlHb in Giardia has not yet been solved. By solving the crystal 
structure of the enzyme, it will give more information of the function of the enzyme and 
possible affect of mutations found in Giardia genes. Interestingly FlHb gene from human 
pathogenic strain, assemblage B, codes for a FlHb that has long extension (about 140 AA) in 
its N-terminus with unknown function. 
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1.5.3 Nitroreductase 1 and 2 are responsible for metronidazole activation/inactivation 
The polypeptide sequence of NR1 is rather similar to that one of NR2. Both proteins contain a 
Fd domain with two 4Fe-4S-clusters at their N-terminus and a FMN-reductase domain at their 
C-terminus (38). The Fd domain found in NR1 is thought to act as a second electron donor for 
the reduction of nitrodrugs, i.e. MTZ (43). The activation may partially reduce nitro 
compounds to toxic intermediates (46).  
 
NR2 on the other hand, decreases the susceptibility to MTZ and detoxify nitro compounds, 
and could thus acts as an inactivator (38, 47). A study (38) observed that under both aerobic 
and semi-aerobic conditions, bacteria expressing giardial NR1 alone had a significantly higher 
susceptibility to nitrodrugs than control bacteria. Bacteria expressing NR2 alone, or both 
nitroreductases, were completely resistant to MTZ (38).   
 
NRs have been identified in Giardia (GL50803_22677 from WB clone C6, and GL50803-
6175). NRs from other anaerobic or microaerophilic pathogens (e. g Helicobacter pylori) 
nitroreductases are well documented as resistance factors (65-67). The biological role of NR1 
and NR2 may be involved in the reduction of vitamin K analogues and FAD (38). To be able 
to understand the MTZ resistant mechanism of Giardia, further investigations are needed. The 
crystal structures of NRs from Giardia have not yet been solved. By solving the crystal 
structure, more information about the enzymes structure function relations can be obtained. 
 
1.6 Production of Giardia proteins 
1.6.1 DNA cloning 
To be able to characterize proteins, they first need to be expressed using for example bacteria 
as host cells, and further solubilized and purified. Before the protein can be expressed, the 
gene of the protein of interest (GOI) needs to be inserted into a vector by cloning. The basic 
principle of DNA cloning is that the DNA of interest is inserted to a cloning vector (also 
known as plasmid), which is further incorporated into cultured host cells. The term “gene 
cloning” includes both in vivo and in vitro cloning. Gene cloning in vivo involves the use of 
restriction enzymes and ligases using vectors and then clone the recombinant DNA into host 
cells. For in vitro gene cloning, the polymerase chain reaction (PCR) method is used to create 
copies (amplify) of DNA (68).  
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For cloning in vivo, a restriction enzyme is required. There are two types of restriction 
enzymes: “blunt end cutters” and “sticky end cutter”. The “blunt end cutters”, cut both the 
strand of the target DNA at the same spot creating blunt ends. Sticky end cutters cut both 
strand of the target DNA at different spots creating 3´- or 5´-overhangs of one to four 
nucleotides. This are called “sticky ends” (69).   
 
Plasmids are circular, double-stranded DNA molecules that are separate from a cell´s 
chromosomal DNA. The circular DNA occurs naturally in bacteria, yeast and also in some 
higher eukaryotic cells. They may exist in a parasitic or symbiotic relationship with their host 
cells. Plasmids are, like chromosomal DNA, duplicated before every cell division. They have 
its independent replication system, which controls the number of copies in a cell. High copy 
numbers gives a higher chance of the daughter cells to contain the plasmid. Low copy 
numbers causes less metabolic burden on their host, but they have a higher probability of loss 
during cell division (70). The plasmids encode for an antibiotic resistance marker, which 
allows the cells containing the plasmid to grow, and kill the plasmid-free cells in a growth 
medium containing the selective antibiotic (71). A cloning vector is a genome that can carry 
and accept DNA. It can increase the number of copies of the DNA of interest through its own 
replication. Vectors are plasmids, and are selected based on the insert size, copy number, 
cloning site, antibiotic resistance and other desired properties important for the use (72).  
 
1.6.2 Recombinant protein expression in Escherichia coli 
The choice of host cell for protein expression depends on different factors. The host systems 
that are available include bacteria, yeast, filamentous fungi, unicellular algae and eukaryotic 
cells (insect and mammalian) (73). They all have strengths and weaknesses that make them 
suitable for different proteins (74). 
 
Escherichia coli (E.coli) is a common host organism for recombinant protein expression. The 
advantage of using E. coli is that it grows fast and it is cost effective. In glucose-salt media 
and optimal environmental conditions, its replication time is about 20 minutes and plasmid 
transformation of E.coli can be performed in as little as 5 min. Plasmids can be put together 
by combinations of replicons, promoters, selection markers, multiple cloning sites, and fusion 
protein/fusion protein removal strategies. The replicon consists of one origin of replication 
together with its associated cis-acting control elements. Promoter sequences are DNA 
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sequences that define where transcription of a gene by RNA begins. The T5 promoter is 
recognized by E.coli RNA polymerase (75). Next to the T5 promoter, a lac operator (lacO) is 
inserted to control the expression. The expression can be turned on by the adding the inducer 
isopropyl β-D-1-thiogalactopyranoside (IPTG), which binds to lacO and turns on the 
transcription (74). The T7 promoter is recognized by the phage T7 RNA polymerase (T7 
RNAP) (74). The system can be induced by IPTG under the control of lacO, or the expression 
can be leaky (74). The T7 promoter can be plain as well, meaning that there are no lacO site 
controlling the expression (76). In this case, the expression is leaky, meaning that there is 
some basal level of protein expression during cell growth (74).  
 
Normal E. coli cells cannot take up plasmid DNA from the environment (77) and the use of 
chemical treated E. coli cells, termed competent cells, are therefore required. Competent cells 
are more permeable for DNA uptake (78).  
 
1.7 Characterization of proteins  
	  
Protein sequencing has earlier been the only method used for elucidating the primary structure 
of proteins. Today, DNA sequencing is used (79). The secondary and tertiary structure of the 
protein is more complicated and often involves multiple techniques. Techniques for finding 
the molecular weight (Mw) of the protein include sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) and other electrophoresis techniques, mass spectrometry 
(MS) and static light scattering (SLS). In order to gain information about the structure of the 
protein, techniques for measuring the ratio of secondary structure including α-helices and β-
sheets with circular dichroism (CD) and techniques for finding the 3D structure such as 
crystallography, can be used (56).  
 
1.7.1 Circular dichroism 
Circular dichroism (CD) is a good method for rapidly evaluating the secondary structure, 
folding and binding properties of proteins. It is a form of light absorption spectroscopy that 
measures the difference in absorbance of right- and left-circularly polarized light by a 
substance (80). A CD signal will occur when a chromophore is chiral (optically active) (81). 
Different structural elements have characteristic CD spectra, which can be recognised from 
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the measured protein solution of interest. α-helical proteins have negative bands at 222 nm 
and 208 nm, and a positive band at 193 nm. β-sheets can be recognized by negative bands at 
218 nm and positive bands at 195 nm (80). By comparing the CD spectra of the protein of 
interest with the known CD spectra of α- β- and random coiled proteins, the secondary 
structure of the protein of interest can be estimated (80).   
 
1.7.2 Static light scattering 
Static light scattering (SLS) is a technique used for measuring the molecular weight of a 
protein in solution. It can be used as a quality control to estimate that it is the right protein in 
the solution, in addition to determine if the protein is monomeric or not (82). The principle is 
based on the relationship between the intensity of light scattered by a molecule and its 
molecular weight and size (83). The intensity of the light is measured as a function of the 
scattering angle, θ. The measured intensity is divided by the intensity of the incident laser 
beam, which is measured by a reference detector (84). If the system uses multiple detector in 
different angles we are talking about multi-angel light scattering (MALS). For a pure protein 
solution, it is expected that all of the protein molecules within the sample should have the 
same molecular weight. SLS is often performed together with size exclusion chromatography 
(SEC) to combine SLS with a purification step (82, 85, 86). The light scattering and 
concentration are measured for each elution fraction, resulting in an independent 
determination of mass and size at the elution position (82). Concentration of the protein 




Thermoflour (Differential scanning fluorimetry) can be used to estimate the apparent melting 
temperature (Tm) of the protein of interest. When the temperature is low, the protein is 
completely and correctly folded and no hydrophobic areas are exposed. When the temperature 
starts to rise, the protein starts to unfold and hydrophobic areas become exposed. A 
fluorescent chemical compound (fluorophore) can now bind to these areas and fluorescence 
occurs. The florescence can be plotted as a function of temperature and form a curve that can 
be used to estimate the melting temperature of the protein by finding the midpoint of the 
transition curve (87).  
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1.7.4 Small angle X-ray scattering  
Small angle X-ray scattering (SAXS) is a high-resolution characterization technique (88). 
This method can be used to study the overall shape and structural transitions of biological 
macromolecules in solution (89). The principle of SAXS is that a X-ray beam is used to 
illuminate the protein in solution, and the scattered radiation is registered by a detector (90). 
The scattering signal from the solvent (buffer) must be subtracted from the protein solution, to 
only get the scattered signal only from the protein. From the scattered data, the molecular 
weight, shape and model for the overall structure of the protein can be obtained (91).  
 
1.7.5 Protein crystallization 
The first protein crystal was observed by Hünefeld in 1840 (92). The protein was hemoglobin 
from earthworm. This observation made it clear that protein crystals could be obtained by 
controlled evaporation of concentrated protein solutions. In other words, protein crystals 
could be produced by slow dehydration (92).  
 
To study the 3D structure of proteins, there are two main techniques: X-ray crystallography 
and nuclear magnetic resonance (NMR) spectroscopy. X-ray crystallography requires protein 
in crystal form, where all protein molecules are lined up in the same orientation (59). 
 
Crystallization is a complicated process, where the parameters have to be individualized. First 
the factors that will make the crystals have to be found, then the individual variables need to 
be optimized to achieve the best possible crystals. When screening for crystallization 
conditions, systematic variation of different important variables such as temperature, pH and 
concentration need to be tested (93).  
 
Crystals can only be grown from a supersaturated solution. Supersaturation is a state where a 
solution contains more of the dissolved material than could be dissolved by the solvent under 
normal circumstances. Supersaturation will occur under specific chemical and physical 
conditions, and the protein solution needs to be pure and homogeneous (93). Different 
methods can be used during the crystallization process, including the sitting-drop vapor-
diffusion method, the hanging-drop vapor-diffusion and microbatch crystallization (93, 94).  
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1.8 Aims of the master project 
	  
The aim of this study is to clone, express and purify the two enzymes NR1 and NR2, which 
are involved in MTZ resistance, and the oxidative stress management enzyme FlHb from the 
pathogenic parasite Giardia lamblia. In addition, structural studies of FlHb should be 
performed in order to characterize the protein structure of FlHb. The structural studies include 
prediction of the secondary structure, stability tests and measure the size of the protein. 
Crystallization trials will be set up in order to obtain crystals, which further can be used to 
obtain the 3D structure of FlHb using macromolecular crystallography.  
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2. MATERIALS  
2.1 Strains and vectors  
2.1.1 Strains 
E. coli Rosetta (DE3) (competent cells prepared by Ju Xu) 
E. coli TOP10 (competent cells prepared by Tiril Ø. Pedersen) 
 
The strains are obtained from the technician, Ju Xu, at laboratory D at the Department of 
Biomedicine, University of Bergen.  
 
2.1.2 Vectors  
pET14b-gFIHb is a low copy vector (<5 copies per cell) that was used as an expression vector 
for wild type Giardia FlHb (gene ID: GL50803_15009 from Giardia assemblage A1 (WB)). 
It has an N-terminal histidine tag (His6-tag) that can be cleaved by thrombin. E. coli Rosetta 
(DE3) is used as an expression host for this gene. The plasmid codes for ampicillin resistance, 
and uses a plain T7 promoter (no lac operator site) so it does not require IPTG induction. 
When a plain T7 promotor is used, the transcription is leaky, meaning that good expression of 
heme-bound protein is obtained without the need of IPTG induction (e.g. use of a lacUV5). 
See Figure 2.1 for the vector map of pET14b.  
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Figure 2.1: Map of the vector pET14b. Created with SnapGene ® Viewer.  
 
pJ401-gFIHb is a high copy vector (>100 copies per cell) that was another vector used for  
expression of wild type Giardia FlHb (gene ID: GL50803_15009 from Giardia assemblage 
A1 (WB)). It has an N-terminal His6-tag that can be cleaved by tobacco etch virus (TEV). In 
this project Rosetta (DE3) was used as the expression host. The plasmid codes for kanamycin 
resistance, uses the T5 promoter and requires IPTG induction. Aminolevulinic acid (ALA) 
may help to obtain more heme-bound protein, as it is a heme precursor. When IPTG induction 
is used, the expression rate is faster than with leaky expression, and it might be that the heme 
synthesis is not keeping up when IPTG induction is required. ALA is therefore added when 




Sequence:  pET-14b.dna  (Circular / 4671 bp)
Enzymes:  Unique 6+ Cutters  (49 of 653 total)
Features:  11 total
Printed from SnapGene® Viewer:  mai 3, 2018  14.09 Page 1
Bacterial vector for expression of N-terminally 6xHis-tagged proteins.









AflIII - PciI(2783)  
BspQI - SapI(2667)  
BstZ17I(2554)  
BsaAI(2535)  
PflFI - Tth111I(2528)  
PfoI(2425)  
BsmBI(2424)  
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Figure 2.2: Map of the vector pJ401-gFlHb with T5 promotor, kanamycin resistance. Map received from Steven 
Rafferty at The Chemistry Department Trent University, Peterborough, Canada. 
 
The vector pETKNI-his-3C-LIC-amp was used for cloning and expression of FlHb from 
assemblage B, NR1 and NR2. It has a His6-tag and ampicillin resistance. The vector is 
compatible with IPTG-inducible expression system in E.coli cell strains. A 3C-preScission 
protease cleavage site is present to remove His6-tag. See Figure 2.3 for the vector map of this 
vector.  
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Figure 2.3: Map of the vector pETNKI-his3C-LIC-amp from NKI protein facility LIC (95).  
 
2.2 Sequences of the proteins of interest 
2.2.1 Flavohemoprotein (assemblage A)  
The FlHb from assemblage A (GL50803_15009) was received from Steven Rafferty at The 
Chemistry Department Trent University, Peterborough, Canada. The gene of interest was in 
advance cloned into the vectors pET14b and pJ401. See Figure 2.4 for the protein sequence of 
FlHb from assemblage A.  
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Figure 2.4: Protein sequence of pET14b-gFlHb. The part marked in blue represents the His6-tag (AA 1-13) and 
the pink part represents the cleavage site (AA 14-19). Picture was created with SnapGene ® Viewer. 
 
The sequence of pJ401-gFlHb is identical from AA 20. The first 13 AA represent the His6-
tag. The following 6 AA (AA 14-19) represent the TEV cleavage site. The cleavage site is 
different for the two constructs. For pJ401-gFlHb, the cleavage site is formed by the AA 
sequence: ENLYFQG, which is recognized by thrombin.  
 
2.2.2 Flavohemoprotein (assemblage B)  
For the FlHb from assemblage B (GSB_151570), three constructs of the protein were ordered 
from Genescript, Piscataway, NJ, USA. The first one is the full length of the protein (595 
AA). The second one is truncated, starting from amino acid number 25 (570 AA in total). 
This one is truncated because the part left out of the structure was predicted to be unstructured 
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from the prediction (by HNN) in the secondary structure while using NKI primer design 
program (96). The third one is truncated as well, starting from amino acid number 138 (457 
AA in total). This truncation is the corresponding construct for the one from FlHb from 
assemblage A. See figure 2.5 for the sequences of the three constructs.  
 
	  
Figure 2.5: Protein sequence of FlHb from assemblage B. The start of each construct of the protein is marked in 
green and the end is marked in red. Three different constructs in total. Picture was created with SnapGene ® 
Viewer. 
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2.2.3 Nitroreductase 1 (assemblage B)  
For the NR1 from assemblage B (GSB_153178), only the full length of the protein (287 AA) 
was used in this project. The construct was ordered from Genescript. See Figure 2.6 for the 
protein sequence of the protein.   
 
	  
Figure 2.6: Protein sequence of NR1. The start of the protein is marked in green and the end is marked in red. 
Picture was created with SnapGene ® Viewer. 
 
2.2.4 Nitroreductase 2 (assemblage B) 
For the NR2 from assemblage B (GSB_22677), two constructs of the protein were ordered 
from Genescript used. The first one is the full length of the protein (264 AA). The second one 
is truncated, and starts from amino acid number 5 (259 AA in total). This one is truncated at 
this point because the vector has a 3C cleavage site, which will after the cleavage leave three 
AA (glycine, proline, glycine). Glycine is original next to tyrosine in the full length (see 
Figure 2.7), leaving only two extra AA in the truncated construct. See Figure 2.7 for the 
sequences of the constructs.  
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Figure 2.7: Protein sequence of NR2. The start of each construct of the protein is marked in green and the end is 
marked in red. Two different constructs in total. Picture was created with SnapGene ® Viewer. 
 
2.3 Equipment  
2.3.1 Tubes  
Table 2.1: List of all tubes used in this project. 
Tubes Producer Catalog number Lot number 
PCR Strips of 8 tubes 
0,2 mL 
BRAND GMBH & 
CO KG, Germany 
781320 579335 
Fisherbrand® PCR 
Strip of 8 with Cap 
Strip, 0,25 mL 
Fisher Scientific, EU 14230215 NA 
SafeSeal tube 
(eppendorf tube),  
1,5 mL 
SARSTEDT AG & 
Co. KG, Germany 
72.706 0647/8043014 
Tube 13 mL, sterile SARSTEDT, 
Germany 
62.515.006 6091811 












Ultracel® - 30 K/10 K 
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Amicon® Ultra-  
0,5 mL, Centrifugal 
Filters, Ultracel® -  
30 K/10 K 







Centrifuge Tube Filter 







Table 2.2: List of all pipettes used in this project. 
Pipettes Producer Catalog number Lot number 
Pipette tip 10 µL SARSTEDT, 
Germany 
70.1130.600 NA 
Pipette tip 200 µL SARSTEDT, 
Germany 
70.760.502 NA 



























Table 2.3: List of the kits used in this project. 
Kit  Producer Catalog number 
PureYield™ Plasmid 
Miniprep System 
Promega, Norway A1223 
Wizard® SV Gel and PCR 
Clean-up System 
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Table 2.4: List of crystallization screens used in this study. 
Crystallization screens Producer Catalog number 
PACT premier ™ Molecular Dimention, UK MD1-29 
JCSG plus ™ Molecular Dimention, UK MD1-40 
SG1 screen ™ Molecular Dimention, UK MD1-89 
 
2.3.4 Columns 
 Table 2.5: Columns used in this project.  
Columns Producer Catalog number Lot number 
Pierce® Centrifuge 
Columns for affinity 




PD-10 Columns for 
buffer exchange 
GE Healthcare, UK 17-0851-01 12881046 
HiLoad 16/600 
Superdex 200 pg, SEC 
GE Healthcare, UK GE28-9893-35  
Superdex™ increase 
200 10/300, SEC 
GE Healthcare, UK 17517501  
 
 
2.3.5 Other consumables 
Table 2.6: List of other consumables used in this project.  











456-1096 L006952 A 
SeaKem® LE Agarose Lonza, USA 50004 0000470886 
LB-Agar (Lennox) Carl Roth GmbH + 
Co. KG 
X965.2 221170173 
LB-Medium (Lennox) Carl Roth GmbH + 
Co. KG 
X964.2 034207346 
T4 DNA polymerase New England 
BioLabs, England 
M0203L 0401706 
Taq DNA polymerase New England 
BioLabs, England 
M0267S 0141706 
FastDigest Kpn1 Thermo Scientific, 
USA 
FD0524 00367902 
          	  	  








Table 2.7: List of buffers from companies used in this study.  
Equipment Producer Catalog number Lot number 
FastDigest Green 
buffer (10X) 
Thermo Fisher  
Scientific, USA 
B72 00337394 
NEBuffer™ 2.1 (10X) New England 
BioLabs, England 
B7202S 0231704 
5X Phusion HF buffer  Thermo Scientific, 
USA 
F-518 00583637 




Additional buffers made in our laboratory are described in appendix 1.  
 
2.3.7 Protocols  
• Molecular methods method “The Inoue Method for Preparation and Transformation of 
Competent E.coli: “Ultracompetent” cells (97). 
• NKI Protein Facility LIC Vectors (95). 
• ACEMBL Expression System, User Manual, EMBL, p. 9-13 (98). 
• Thermo Scientific, User guide: FastDigest KnpI (99). 
• One-Step Sequence- and Ligation-Independent Cloning as a Rapid and Versatile 
Cloning Method for Functional Genomics Studies (100). 
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2.3.8 Instruments 
Table 2.8: List of all instruments used in this project. 
Instrument  Use Producer 
VCX130, Ultrasonic 
Processor for Small Volume 
Applications 
Sonication for cell lysis Sonics & Materials, Inc, 
USA 
WPA CO 8000 Biowave Cell 
Density Meter 
Measure OD600 Biochrom Ltd, England 
SORVALL RC-5C Plus 
Centrifuge 
Centrifugation of higher 
volumes and high speed 
DuPont, USA  
Eppendorf Centrifuge 5810 
R 
Centrifugation of higher 
volume 
Eppendorf 
Eppendorf Centrifuge 5415 
D 
Centrifugation of smaller 
volume 
Eppendorf 
CERTOMAT® IS Incubation of small scale 
bacteria culture 
Sartorius, Germany 
Allegra® X-15R Centrifugation of high 
volume 
Beckman Coulter, USA 
Innova 4430 Incubator 
Shaker 
Incubation of big scale 
bacteria culture  
New Brunswick Scientific 
Co,. Inc., USA 
Eppendorf Thermomixer 
comfort, 1,5 mL 
Heating, cooling and shaking 
of eppendorftubes (1,5 mL) 
Eppendorf 
MiniSpin® Centrifuge small volumes 
(1,5 mL) 
Eppendorf 
Thermaks TS 8056 Drying oven Termaks AS, Norway 
Heto OBN 8 Warm bath Heto Lab Equipment  
PowerPac® Basic Power 
Supply 








MyCycler™ thermal cycler PCR Bio-Rad Laboratories, 
Norway 
ChemiDoc™ XRS+ with 
Image Lab™ Software 








Measure concentration  Thermo Fisher Scientific, 
USA 
miniDAWN TREOS SLS (MALS) Wyatt technology, USA 
RefractoMax 520 Measure the RI for 
concentration determination  
ERC, Germany 
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during SLS 
Spectropolarimeter J-810 Measure CD JASCO, Japan 
Mosquito® LCP Preparation of crystallization 
plates 
TTP Labtech,  
ROCK IMAGER® 182 Imaging of crystallization 
plates 
Formulatrix, USA 
LightCycler® 480 II Thermofluor assay Roche, Switzerland 
ÄKTApurifier SEC (preparative and SLS) GE Healthcare  
Systec HX-320 Autoclave Systec GmbH, Germany 
 
2.3.9 Software  
 
• Microsoft® Word for Mac 2011 (Microsoft corporation) was used for writing this 
thesis. Microsoft®. 
• Excel for Mac 2011 (Microsoft corporation) was used to make diagrams and to 
transfer data from instruments.  
• ATSAS online GASBOR was used to create the overall structure of the proteins with 
data from SAXS (102). 
• Primus was used for processing and analysing of data from SAXS (103). 
• SnapGene® Viewer 4.1.5 (GSL Biotech LLC) was used to compare sequences from 
sequencing and ordered sequences, and to create protein sequence figures.  
• ASTRA 6 (Wyatt technology, USA) used for SLS.  
• ND-1000 V3.5.2 (Thermo Fisher Scientific, USA) for measurements at NanoDrop®. 
ND-1000 UV-Vis Spectrophotometer. 
• Spectra Manager for measurement of CD with Spectropolarimeter J-810. 
• UNICORN 5.01 (GE Healthcare) used to create elution profile and collect fractions 
from SEC.  
• ExPASy translate tool (104) for translate DNA sequences into protein sequences.  
• ExPASy ProtParam tool (105) to compute various physical and chemical parameters 
for the proteins of interest. 
• NKI primer design (96). 
• PyMOL Molecular Graphics System, version 2.0.6 (Schrodinger LLC, USA). 
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3. METHODS 
 
3.1 Preparing the competent cells (TOP10) 
In order to make competent cells, the protocol described in Molecular methods “The Inoue 
Method for Preparation and Transformation of Competent E.coli: “Ultracompetent” cells (97) 
was used.  
 
 E.coli cells were incubated in super optimal broth (SOB) medium at 20 °C with shaking at 
250 revolutions per minute (rpm) overnight. 100 mL of Inoue transformation buffer (ITB) 
was made. The cultures were incubated until OD600 reached 0.55 (measured with WPA CO 
8000 Biowave Cell Density Meter) and then they were transferred to an ice-bath for 10 min. 
The cells were harvested by centrifugation at 2500 x g for 10 min at 4 °C (Allegra X-15R 
Centrifuge). The cells were resuspended gently in 80 mL of ice-cold ITB and harvest again 
with the same centrifugation procedure. Further the cells were resuspended in 10 mL ice-cold 
ITB and 750 µL of dimethyl sulfoxide (DMSO) was added. Lastly the cells were dispensed 
into chilled eppendorf tubes in a cold room (4 °C) followed by a snap-freeze in a bath of 
liquid nitrogen.  
 
3.1.1 Transformation into competent cells  
Plasmid (0.5 µL) was added into competent cells, TOP10 (100 µL), and incubated on ice for 
30 min. After incubation the cells were shock-heated at 42 °C (water bath) for 45 sec and 
immediately put back on ice for at least 2 min. Then 500 µL Luria-Bertani broth (LB) 
medium was added to the cells and incubated at 37 °C for approximately 1 h with shaking at 
700 rpm (using CERTOMAT® IS). 50 µL of transformation mixture were plated on LB agar 
plates containing antibiotics. The plates were incubated overnight at 37 °C (Thermaks TS 
8056). One culture from each of the agar plates was transferred to a flask containing LB 
media and antibiotics. Flasks were incubated overnight at 37 °C with shaking at 250 rpm 
(CERTOMAT® IS).  
 
LB medium was prepared by Ju Xu, at laboratory D at the Department of Biomedicine, 
University of Bergen. LB agar plates were prepared by adding 8.75 g LB-Agar (Lennox) into 
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250 mL water and autoclaved (Systec HX-320). Mixture was microwaved until the hard part 
was dissolved, cooled down to room temperature (RT) and divided into plates.  
 
3.1.2 Plasmid isolation 
Miniprep is a rapid method for isolating smaller amount of plasmids, which have been 
amplified in E.coli bacterial cells (106). Plasmid isolation was done using Miniprep kit 
(PureYield™ Plasmid Miniprep System), and the manufacture protocol. After transformation 




Sequence- and ligation-independent cloning (SLIC) method was used. The gene of interest 
(GOI) is PCR amplified with specific primers and the vector is linearized. The PCR amplified 
product and the linearized vector are separately treated with T4 DNA polymerase. T4 DNA 
polymerase acts as an exonuclease in the absence of dNTP and produces long sticky 
overhangs. The T4 DNA polymerase treated GOI and vector are mixed and annealed, 
followed by transformation, yielding a single gene expression cassette (98). The cloning was 
done using ACEMBL Procedure (98).  
 
3.2.1 Primer design 
Primers for the insert contain a DNA sequence complementary for the GOI, and overhangs, 
the corresponding to a region of sequence in the expression vector. In this case where NKI 
vectors are used, it is the site where the vector is linearized using Kpn1 enzyme. These 
overhangs result in the long sticky end upon treatment with T4 DNA polymerase in the 
absence of dNTP. Primers were design from each of the regions marked with a green start and 
red stop in the protein sequences. See Figures 2.5-2.7. Forward and reverse primers are 
designed to have identical Tms (melting temperatures) for the PCR to be successful.  
 
NKI primer design (96) was used for designing primers for NR1, NR2 and FlHb assemblage 
B.  
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3.2.2 Polymerase chain reaction  
 PCR is a widely used method for amplifying specific DNA sequences. The reaction consists 
of three steps; denaturation, annealing and extension. In the denaturation step, the two strands 
of the parent DNA are separated by heat (98 °C). Further in the annealing step, the 
temperature is cooled down to the Tm of the primers, so the primers can bind to their 
complementary sequence on the single strand template DNA. In the last step, the temperature 
is increased (72 °C) in order for Taq polymerase to extend the primers and synthesizes new 
strands of DNA. The steps are repeated in 25-35 cycles (107). The result of a successful PCR 
experiment, depends on the primer design, the time in each step and the temperature (108).  
 
The protocol from ACEMBL (98) was used for PCR amplification of insert and vector, with 
some adjustments (Table 3.1). 
 
Table 3.1: Components added in PCR tubes before PCR run, using 2X Phusion HF Master 
Mix.  
Reagents  Amount added  
ddH2O  Add up to 25 µL 
2X Phusion HF PCR 
Master Mix with HF 
buffer  
12,5 µL 
Forward primers FlHb_FW_1 1 µL 
 FlHb_FW_26 1 µL 
FlHb_FW_138 1 µL 
NR1_FW_1 1 µL 
NR2_FW_1 1 µL 
NR2_FW_5 1 µL 
Reverse primers FlHb_RV_595 1 µL 
 NR1_RV_287 1 µL 
NR2_RV_264 1 µL 
Template DNA  FlHb 1 µL ≈ 103,7 ng 
 NR1 1 µL ≈ 55,6 ng 
NR2 1,5 µL ≈ 47,6 ng 
Total amount added  25 µL 
 
All components used for PCR reaction of the insert (gene of interest) is given in Table 3.1. 
All PCR tubes contained water (ddH2O) and master mix, with different template DNA and 
one corresponding forward primer and the corresponding reverse primer. The template DNA 
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for FlHb was divided into three PCR reactions (1:FlHb_FW_1 and FlHb_RV_595, 2: 
FlHb_FW_26 and FlHb_RV_595, 3:FlHb_FW_138 and FlHb_RV_595). Similarly two PCR 
reactions were used for NR2 (1:NR2_FW_1 and NR2_RV_264 and 2:NR2_FW_5 and 
NR2_RV_264). For NR1, one PCR reaction was used (NR1_FW_1 and NR1_RV_287).  
 
All of the prepared PCR tubes were run in the PCR instrument (MyCycler™) at this program:   
1 x 98 °C 
35 x [98 °C for 10 sec. à 65 °C for 30 sec. à72 °C for 2 min] 
1 x 72 °C for 10 min 
 
The amplified PCR product was then loaded on 1 % agarose gel: 
2 µL of PCR sample and 0.5 µL of dye (6x loading buffer + green dye). 1 X tris-acetate-
EDTA (TAE) buffer was filled in the chamber until it covered the gel. Run at 100 V for 60 
min with PowerPac 200 Electrophoresis Supply.  
 
The rest of the PCR products were loaded on gel one more time with the same run. Each band 
from each of the genes was cut out of the gel. The gel bands were cleaned with PCR cleaning 
kit (Promega, Wizard® SV Gel and PCR Clean-up System).  
 
1 % agarose gel was prepared by adding 0.5 g SeaKem® LE Agarose and 50 mL of 1 X TAE 
buffer into a flask. Mixture was microwaved until the agarose powder was dissolved, and 
poured into suitable forms with a comb to make the wells. The gel was solid after 
approximately 15 min.  
 
3.2.3 Linearization of the vector 
The vector (pETNKI-his3C-LIC-amp) was linearized with the enzyme Kpn1. The protocol 
from Thermo Scientific FastDigest KnpI was followed with some modification: 
 
pETNKI-his3C-LIC-amp (20 ng/ µL) 40 µL 
Kpn1 enzyme      3 µL 
10 X Fast Digest Green Buffer    5 µL 
ddH2O       2 µL 
Total       50 μL 
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The components in 3.2.3 were mixed together. The mixture was incubated at 37 °C for 2 h. 
Kpn1 was inactivated at 80 °C for 5 min before the mixture was loaded on 1% agarose gel 
with dye (50 µL vector mixture + 8 µL (6x loading buffer + green dye)). The bands on the gel 
were cut out and purified with PCR cleaning kit (Promega, Wizard® SV Gel and PCR Clean-
up System).  
 
3.2.4 T4 DNA polymerase exonuclease treatment  
All the inserts and the linearized vector (pETNKI-his3C-LIC-amp) were treated with T4 DNA 
polymerase. Two different methods were tested. The first method follows the ACEMBL 
protocol (98) were the inserts and the vectors are treated separately before they are mixed 
together. Separately they are incubated at 23 °C for 20 min, 1 µL of EDTA is added, and then 
they are inactivated at 75 °C for 20 min. After mixing, they are annealed at 65 °C for 10 min 
and then slowly cooled down to RT in a heat block. Following components were mixed in 
each PCR tube:  
 
10 X NEB 2.1 buffer  1 µL 
100 mM DTT   0.5 µL 
2 M Urea   1 µL 
Insert/ vector   7 µL 
T4 DNA polymerase  0.5 µL 
Total     10 μL 
 
The second method is a one-step treatment (100) where the insert and the vector are first 
mixed, and then treated with T4 in the same tube. The mixture was incubated at 50 °C for 30 
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Linearized vector   1 µL 
Insert    3 µL 
10 X NEB 2.1 Buffer  1 µL 
100 mM DTT   1 µL 
T4 DNA polymerase  0.2 µL 
Water    4 µL 
Total     10 μL 
 
All the T4 DNA treated samples were transformed into competent cells (TOP10) with 
standard transformation procedures. Colonies from the transformation were run with PCR to 
check if the cloning had worked.  
 
Colony PCR were run with Taq DNA polymerase with following components added to each 
PCR tube:  
 
10 X ThermoPol buffer 2.5 µL 
10 mM dNTPs  0.5 µL 
10 µM FW primer  0.5 µL 
10 µM RV primer  0.5 µL 
1 bacteria colony from agarplate  
Taq DNA polymerase  0.125 µL 
Water    20.9 µL 
Total     25 μL 
 
PCR program: 
95 °C for 30 sec 
[95 °C for 15 sec, 65 °C for 30 sec, 68 °C for 2 min] x 30 cycles  
68 °C for 5 min 
 
The finished PCR products (2 µL of PCR sample + 0.5 µL of dye (6x loading buffer + green 
dye)) were loaded on 1 % agarose gel to check if the PCR was successful. Run at 100 V for 
40 min.  
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3.2.5 Sequencing  
Positive colonies from colony PCR were sent for sequencing (at the Sequence laboratory on 
the 6th floor of the Laboratory building, Center for Medical Genetics and Molecular Medicine, 
Haukeland University Hospital). First the colonies from the fresh agar plates were transferred 
to LB media and bacteria was cultured at 37 °C with shaking (250 rpm) overnight. The 
plasmid DNA was isolated from the bacteria media before following components were mixed 
in each PCR tube:  
 
Big dye 3.1    1 µL 
Sequencing buffer   1 µL 
T7 primer (FW or RV) 1 µL 
Plasmid DNA   3 µL (200 ng) 
Water    4 µL (up to 10 µL) 
Total    10 μL 
 
PCR program: 
96 °C for 5 min 
[96 °C for 10 sec, 50 °C for 5 sec, 60 °C for 4 min] x 25 cycles  
10 °C ∞ 
 
10 µL water was added to the each PCR tube after the PCR reaction before they were sent for 
sequencing.  
 
3.3 Protein expression  
3.3.1 Expression of flavohemoglobin from assemblage A 
pJ401-gFlHb was transformed into Rosetta (DE3) cells with the transformation procedure 
described earlier (3.1.1) using antibiotics, kanamycin and chloramphenicol for the overnight 
culture. Bacteria culture (5 mL) was then added to two different Fernback flasks of terrific 
broth (TB) media (1 L). ALA 0.1 mM and Potassium hexacyanoferrate (III) (K3Fe(CN)6) 0,01 
mM were added to one Fernback flask of TB media (1 L) and only K3Fe(CN)6 was added to 
the other Fernback flask of TB media (1 L). Antibiotics were added as well, both kanamycin 
and chloramphenicol. The flasks were incubated at 37 °C with shaking (200 rpm) (Innova 
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4430 Incubator Shaker) until the cells reached an OD600 of 0.4-0.5 (WPA CO 8000 Biowave 
Cell Density Meter). 1 mM IPTG was added to both flasks and incubated further overnight at 
20 °C (Innova 4430 incubator shaker). An aliquot (1 mL) was taken after 0,17 and 24 hours, 
centrifuged (maximum speed with MiniSpin® for 1 min) and the pellets collected. After 24 
hours of incubation, the cells were collected by centrifugation at 4000 g for 20 min at 4 °C. 
The medium was discarded and the cells were scrapped with a spatula and put on Falcon 
tubes.  
 
pET14b-gFlHb was transformed into Rosetta cells in the same way as pJ401-gFlHb, but with 
ampicillin and chloramphenicol as antibiotics. The bacteria culture (5 mL) was added to a 
Fernback flask of TB media (1 L) together with ampicillin (1 mL) and chloramphenicol (1 
mL). The flask was incubated with the same procedure as the pJ401-gFlHb culture, but 
without the IPTG induction. Aliquots and the cells were collected in the same way as for 
pJ401-gFlHb.  
 
3.3.2 Expression of flavohemoprotein138 
Expression using the pETNKI vector was done after the cloning. For the truncated FlHb138 
(starting from AA 138 from Figure 2.5) the same procedure as described in 3.2.1 was done, 
except the K3Fe(CN)6 was replaced with the 1000 X trace elements (109) (0.2 mL in 1L TB 
media), to provide a supply for the iron in ferrous state.  
 
3.3.3 Expression of nitroreductase 1 
For the NR1, the same procedure as for FlHb138 was followed (described in 3.2.2), except for 
the addition of ALA. 1 mM IPTG was added when the OD600 reached 0.7.  
 
For NR1, auto-induction was also tested. The ZYM-5052 medium (109) for auto-induction 
was used. After transformation into Rosetta cells, the bacteria culture was added into a 
Fernback flask with ZYM-5052 medium (1L). The flask was incubated at 37 °C with shaking 
(200 rpm) for 2 hours, then the temperature was lowered to 18 °C and the cells were 
incubated over the weekend (64 hours). The cells were collected in the same way as described 
in 3.2.1.  
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3.4 SDS-PAGE 
SDS-PAGE is a method for separating proteins based on their molecular weight. As proteins 
move through the gel in response to an electric field, the gel´s pore structure allows smaller 
proteins to travel more rapidly than lager proteins. The SDS-PAGE system is a discontinuous 
denaturing system. The proteins become fully denatured and dissociate from each other by 
heat in the presence of SDS and the reducing agent, β-mercatoethanol (β-ME), which breaks 
possible disulfide bonds (110).  
 
All the pellets from each of the sample were resuspended in 0.5 mL buffer mixture of 20 mM 
Hepes buffer + 150 mM NaCl with a pipette. The suspension was sonicated for 10 seconds 
with amplitude of 70. Further 20 µL from each of the samples was transferred to eppendorf 
tubes. Then the remains were spun down at 13.4 rpm (maximum speed) for 5 min. 20 µL of 
the supernatant was transferred to new eppendorf tubes. 5 µL of SDS (+ 1 % β-ME in SDS 
buffer) loading buffer (5 X) was added to all of the eppendorf tubes. The tubes were heated at 
95 °C for approximately 5 min (Eppendorf Thermomixer). 8 µL of each sample loaded on the 
gel (Mini-PROTEAN® TGX™ Precast Gels) together with 2 µL of marker. The chamber was 
filled with 1 X running buffer. The gel was set to run at 200 V for 35 min with PowerPac®. 
The gel was stained with Instant blue.  
 
3.5 Protein purification 
3.5.1 Ni-NTA affinity chromatography 
Affinity chromatography is based on specific binding of the compound of interest to the 
stationary phase. When the solution is passed through the column, the compound of interest is 
bound. A washing step is then done using wash buffer and the one adhering compound is 
eluted by changing the condition (111). This purification method is highly selective for the 
protein of interest. In this case, the protein of interest has a string of histidine residues (called 
His-tag) on protein N-terminus. The tagged proteins are then passed through a column of 
beads containing covalently attached, immobilized nickel (II). The His-tag binds tightly to 
nickel and will therefore also bind the protein of interest while other proteins flow through the 
column. The protein can be eluted from the column by adding imidazole, which binds to the 
metal ions and displaces the protein (59). 
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The following buffers (see appendix 1) were used for the purification of the different proteins:  
• pJ401-gFlHb, pET14b-gFlHb and  FlHb138: Lysis buffer 1, wash buffer 1 and elution 
buffer 1 
• NR1: Lysis buffer 2, wash buffer 2 and elution buffer 2 
 
The pellet collected from expression was resuspended by pipetting in 30 mL of lysis buffer 
with lysozyme (0.1 mg/mL). The addition of lysozyme will help to break the cell walls. The 
cells were then lysed by sonication 4 x 2 min, 10 sec pulses and 23 W. The lysate was 
centrifuged using SS-34 rotor with the speed of 17 000 rpm for 30 min (SORVALL RC-5C 
Plus centrifuge). After the centrifugation, the supernatant containing the soluble proteins was 
collected.   
 
To prepare the column ready, 2 mL of Ni-NTA was added to Pierce® Centrifuge Columns, 
and washed with water to remove ethanol from the Ni-NTA subsequently followed by a lysis 
buffer wash. Then the supernatant was added to the column and mixed with the Ni-NTA by 
pipetting. The column was opened and the contents were eluted. Then the column was washed 
with 15 mL of washing buffer 3-4 times. Aliquots (50 µL) from each wash was collected to 
measure the amount of protein left in each wash, and to validate the amount of washing steps 
needed to remove contaminants. The concentration was measured by nanodrop 
(Spectrophotometer) at 280 nm. Iron (1 mM Fe(CN6)) was mixed with washing buffer (1 mL 
in total) and added to the column before the last wash, to get the heme in the protein to ferric 
state. When the washing was done, 6-8 mL elution buffer was added. The protein was then 
eluted from the column and collected. Buffer exchange was done with a PD10 column to 
remove excess of imidazole.  
 
If it was not possible to continue to the next purification step the next day, the protein solution 
of both FlHb assemblage A and FlHb138, was frozen down by snap freezing with nitrogen 
and stored at -80 °C.  
 
3.5.2 Size exclusion chromatography   
Size exclusion chromatography (or gel filtration chromatography) is a method for separating 
molecules by their size. This is often used as a last purification step after at least one other 
purification step. The larger molecules will be eluted first and the smaller molecules will be 
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eluted later (86). Small molecules penetrate the pores in the stationary phase, and larger 
molecules do not. Because small molecules must pass through an effectively larger volume, 
the large molecules will be eluted first (111). The beads of gel filtration columns consist of 
cross-linked polyacrylamide, agarose, dextran, or a combination. Depending on the molecule 
size, it may or may not enter the beads. By using this method we can separate and collect 
different size species, in addition to estimate how much of the protein is a monomeric form 
and how much has aggregated or formed oligomers (112). The detection happens by 
monitoring absorbance at 280 nm. 
 
Depending on the protein solution volume, two different columns and loops were used. For a 
sample volume of 1 mL, the loop size was 1 mL and the column used was HiLoad 16/600 
Superdex 200 prep grade. For smaller volumes like 250 µL, the size of the loop was 250 µL 
and the column used was Superdex™ 200 increase 10/300.  
 
For all FlHb constructs, gel filtration buffer 1 was used and for NR1 gel filtration buffer 3 was 
used. The buffer of use was in advance filtered and degassed to avoid introducing air in the 
column. Before the protein solution was injected into the instrument, it was filtered with 
Costar® Spin-X Centrifuge Tube Filter 0,22 µm, 2 mL, non-sterile.  
 
Gel filtration was done prior the crystallization screening of FlHb, to make sure that the 
sample is pure. In this case, FAD (1 mM) and K3Fe(CN)6 (1 mM) was added to the protein 
solution before filtration. The buffer of use was gel filtration buffer 2. HiLoad 16/600 
Superdex 200 prep grade column was used for 2 mL of protein solution. Fractions from the 
elution profile were collected in a 96-well plate.  
 
3.6 Concentrating the proteins  
	  
The purified protein solutions (up to 10 mL) were concentrated to the wanted concentration 
by adding the protein solution to Amicon® Ultra-15 Centrifugal Filters, Ultracel® (30 K for 
FlHb, 10 K for NR1), and centrifuged at 3900 rmp for approximately 10 min (depending on 
the concentration) at 4 °C using Eppendorf Centrifuge 5810 R.  
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For smaller volumes of protein solutions (up to 0.5 mL) Amicon® Ultra-0.5 mL Centrifugal 
Filters, Ultracel® was used, and centrifuged at maximum speed for approximately 2 min at 4 
°C using Eppendorf Centrifuge 5515 D.  
 
Measuring the concentration of the purified protein was done both with spectrophotometer 
(nanodrop A280) and with refractometer (Anton Paar Abbemat 500 Refractometer).  
 
3.7 His-tag cleavage 
3.7.1 His-tag cleavage using TEV 
For pJ401-gFlHb, the His6-tag can be cleaved by TEV protease. TEV protease has a 
chymotrypsin-like fold with an atypical catalytic triad in which cysteine replaces serine, and 
exhibit an absolute requirement for glutamine in the P1 position of their substrates (113).  
 
1) After the size exclusion chromatography, FlHb fractions from the elution profile, was 
collected and concentrated to half the volume (400 µL). 1 mM DTT and 20 µL TEV was 
added to the protein solution. DTT is a reducing agent used to reduce protein disulfide bonds. 
Aliquots (20 µL) were taken right after TEV was added, after 2 hours and after 18 hours, and 
analyzed on SDS-PAGE.  
 
2) 150 µL TEV was added to 3 mL of protein solution (2,59 mg/mL) in a dialysis tube. The 
tube were placed in dialysis buffer 1 (see appendix 1) and left overnight for dialysis at 4 °C. 
 
3) 125 µL flavohemoprotein was added in 500 µL dialysis buffer 1 (appendix 1) and 20 µL 
TEV protease was added to the protein solution. Two samples of this mixture were prepared, 
one sample was incubated in room temperature and one sample was incubated at 30 °C 
overnight. Aliquots (20 µL) were taken after 0, 2, 4 and 24 hours and analyzed on SDS-
PAGE. 
 
Analyzes using SDS-PAGE were done to check if the cleavage had worked. If there was a 
shift in the band sizes comparing with and without TEV, the cleavage had worked. If the 
SDS-gel did not give a clear result, another method was used. This method was to run the 
protein solution with TEV through a Ni-NTA column. If the His6-tag had been cleaved off, 
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the protein would no longer bind to the resin, but follow out through the column and be in the 
flow through.  
 
3.7.2 His-tag cleavage using thrombin 
For pET14b-gFIHb the His6-tag can be cleaved off by thrombin. The first cleavage trial was 
done by adding 10 units of thrombin per mg protein to the protein solution. The mixture was 
left on ice overnight. A second trial was done in RT overnight. This time one sample 
contained 50 units of thrombin per mg protein and one sample contained 100 units per mg 
protein. To confirm if the cleavage had worked or not, the same methods as described in the 
section above (3.7.1), were used.  
 
3.7.3 His-tag cleavage using 3C protease 
For the constructs cloned into the vector pETKNI-his-3C-LIC-amp, the His6-tag can be 
cleaved off with 3C protease. 3C protease was added to the affinity purified FlHb138 with a 
ratio of 1:10. The mixture was left at 4 °C overnight. To confirm if the cleavage had worked 
or not, the same methods as described in the section above (3.7.1), were used. 
 
3.8 Characterization of protein  
All characterization was done with FlHb from assemblage A, expressed with pET14b-gFlHb.  
 
3.8.1 Peptide mass fingerprinting 
Peptide mass fingerprinting (PMF) is a protein identification technique. The protein of 
interest is digested with trypsin yielding a defined number of peptides of specific length and 
mass. These peptides with specific masses are unique to a protein. The peptides are analyzed 
by using mass spectrometry (MS). The protein of interest can be identified by comparing the 
list of peptide masses (peptide sequences) from the protein of interest to a peptide list of a 
database protein (114).  
 
PMF was used to confirm that the bands from SDS-PAGE gels were the right proteins. The 
bands were cut out from the gel, and put in eppendorf tubes. The samples were sent to Ulrich 
Bergmann at University of Oulu, who performed the PMF.   
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3.8.2 Multi angle light scattering  
MALS was done in combination with chromatography (SEC system), SEC-MALS. By using 
the combination, the chromatography system will remove problems related to purity and 
prepare the sample for FlHb assemblage A. With SEC, the different size species were 
separated, followed by measurement of RI signal for the sample and light scattering (LS) data. 
Sample’s concentration from UV or RI can then be combined with LS data. The concentration 
source used in this case was RI. A MALS detector collects scattered lights at many angles. It 
can measure molecular weight for both isotropic and anisotropic scatters.  
 
The FlHb protein sample purified from His-tagget Ni-NTA affinity chromatography, was 
filtered with Costar® Spin-X Centrifuge Tube Filter 0.22 µm, 2 mL, non-sterile. The buffer 
used for SEC-MALS was phosphate-buffered saline (PBS). 
 
In addition, SEC-MALS was performed by Erik Hallin at Diamond Light Source, Harwell 
Science & Innovation Campus, England, in conjunction with SAXS. The sample preparation 
is described in 3.8.5.  
 
3.8.3 Circular dichroism  
CD was done with FlHb from assemblage A. The protein solution was dialysed against 
dialysis buffer 2 (appendix 1) overnight in cold room, using a dialysis button. The start 
concentration of the protein solution was 0.71 mg/mL. The protein was run on the CD 
instrument, but the concentration needed to be lowered as the detector was saturated. For 
measuring the CD spectrum, a protein concentration of 0.175 mg/ml was used. With the given 
concentration, a run where the CD spectra are measured as a function of temperature was 
done to estimate the Tm of the protein.   
 
Two peaks were seen close to each other in the elution profile from SEC, therefor it was 
desirable to compare the secondary structure of the proteins from these two peaks. This was 
done with CD. FlHb assemblage A was run with SEC with gel filtration buffer 2 (appendix 1). 
Fractions were collected from SEC respectively to the two peaks. CD spectra were compared.  
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3.8.4 Thermofluor 
A thermofluor assay was performed to determine the Tm and to screen for the optimal buffer 
condition where FlHb assemblage A is most stable. First a thermofluor buffer/salt screen was 
made in a 2-mL deep 96-well block. See Table 3.3 for the different condition in each well. 
Second the thermoflour plate was prepared with 16 µL of each condition from the screen, 1 
µL 5.28 mg/ml protein and 3 µL of 100x SYPRO Orange in 50 % DMSO in each well of the 
plate (96 wells in total). The plate was placed in the instrument LightCycler® 480 II, where 
the thermofluor assay was performed.  
 
Table 3.3: Buffer and salt screening components for the ThermoFluor. 
 
1 2 3 4 5 6 7 8 9 10 11 12 SALT 
A 

































tris, pH 6 
20 mM 
Tris, pH 7,5 
20 mM 




Tris, pH 7,5 
20 mM 
Tris, pH 8,5 
	   
No additives 10 mM MgCl2 
50 mM (NH4)2SO4 10% glycerol 
 
3.8.5 Small angle x-ray scattering  
The sample was carefully purified with Ni-NTA affinity purification and then stored on ice 
until it was measured. The concentration of this sample was 10.5 mg/mL. SEC coupled SAXS 
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The SAXS experiment was executed by Erik Hallin at Diamond Light Source, Harwell 
Science & Innovation Campus, England. Collected SEC-SAXS frames were processed using 
a script written by Hallin. Data was processed and analysed using Primus (103) from ATSAS 
package. Models were created using GASBOR (102).  
 
3.9 Protein crystallization  
Protein concentration of 12.67 mg/mL was used for initial crystallization screening for the 
FlHb assemblage A. 1 mM FAD was added to half of the protein solution. Sitting drop 
vapour-diffusion method was used. Plates were prepared using Mosquito HT crystallization 
robot. One droplet contained FlHb and one droplet contained FlHb + FAD mixed 1:1 with 
crystallization solution. MRC SD2 96 well plate was used for the droplets. Crystallization 
screens JCSG-plus HT 96 and PACT-premier was used for screening for optimal 
crystallization conditions. The plates were stored in 20 °C and each droplet were imaged by 
ROCK IMAGER® 182.  
 
New plates were set up with lower concentrations of FlHb from assemblage A (9 mg/mL and 
4.7 mg/mL) and FAD (1 mM) added to all of the droplets. Crystallization screen PACT-
premier and JCSG-plus HT 96 were used. The plates were stored in 20 °C and each droplet 
were imaged by ROCK IMAGER® 182. 
 
More screening was done to find the optimal crystallization condition. 4 new crystallization 
plates were prepared. Two plates containing PACT-premier and two plates containing SG1. 
Fe and FAD were added to the protein solution before gel filtration, and the concentration of 
the solution was 10.3 mg/ml. One plate with PACT and one plate with SG1 were put in 8 °C, 
and the other two plates were put in 20 °C.  
 
Crystallization plates were also set up directly after affinity purification and buffer exchange. 
The buffer used was gel filtration buffer 1 (appendix 1). The protein concentration for this 
experiment was 11.1 mg/mL. Plates were set up with the crystallization screens JCSG-plus 
HT 96, PACT-permier and SG1. The plates were stored in 20 °C and each droplet were 
imaged by ROCK IMAGER® 182. 
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Two different fractions from SEC were collected and new trials for crystallization were set 
up. The buffer used for SEC was gel filtration buffer 1 (appendix 1). The concentration of the 
colorless fraction was 9.3 mg/mL and the concentration of the colourful fraction was 10 
mg/mL. The same crystallization screens were used (JCSG, PACT and SG1). The plates were 
stored in 20 °C and each droplet were imaged by ROCK IMAGER® 182. 
 




          	  	  




4.1.1 Primer design 
Primers in Table 4.1 were designed:  
 
Table 4.1: Primers designed in this study 
Gene Base 
pair 




 1710 FlHb_FW_25 
 
CAGGGACCCGGTCGTAAAGCACCGGCATGG 
 1371 FlHb_FW_138 CAGGGACCCGGTATGCCGCTGAGCGAAGATA 









 777 NR2_FW_5 CAGGGACCCGGTATTTTTGCGACCCTGAATATGAG 
  NR2_RV_264 CGAGGAGAAGCCCGGTTAAACACCTAAAACAAATGCCAGC 
 
The part of the sequence marked in red, is the “overhang” of the primer, which is 
complementary to the vector backbone. The black part of the sequence is the complementary 
region for the GOI. Tm of the primers are estimated to 60-65 °C.  
 
4.1.2 Cloning and transformation into competent cells 
PCR was done to amplify each of the protein coding sequence from synthetic genes from 
assemblage B. The PCR products were run on a 1 % agarose gel, stained with GelGreen and 
imaged under UV-light. The results from the gel electrophoresis indicate the size of the PCR 
products. The picture (Figure 4.1) shows bands corresponding to the expected size of genes of 
          	  	  
	   49	  
interest. FlHb is approximately 1400-1800 base pair (bp) in size (see Table 4.1) 
corresponding to 1.4-1.8 Kb in the Figure 4.1. NR1 and NR2 are corresponding to their gene 
length of 0.8-0.9 Kb (Figure 4.1). 
 
	  
Figure 4.1: Electrophoresis in 1% agarose gel stained with GelGreen. Bands representing PCR amplification of 
FlHb1, FlHb25, FlHb138, NR1, NR2 1 and NR2 5.  
 
The bands from the gel were then cut out from the gel and purified with PCR cleaning kit, 
resulting the final concentrations of the genes after the cleaning which were rather low (see 
Table 4.2)  
 
Table 4.2: Concentrations of the amplified genes after they are purified from 1 % agarose 
gel.  
Gene Concentration (ng/µL) 
FlHb 1 9.8 
FlHb 25 14 
FlHb 138 6.5 
NR1 4.8 
NR2 1 7 
NR2 5 10.7 
 
The vector, pETNKI-his-3C-LIC-amp, was linearized, cut out of the gel and purified. Figure 
4.2 shows a shift in the bands, which indicates that the linearization was successful. The 
linearized vector seems larger than the circular plasmid on the gel even though the size of the 
plasmid is the same. The circular plasmid can be observed in four different forms: circular 
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relaxed (niked), circular supercoiled and circular single stranded (115). The conformational 
changes of the plasmid will affect their movement during gel electrophoresis (116). 
Supercoiled plasmid will move faster than relaxed plasmid because it is tightly coiled and 
more compact resulting in less frictional resistance from the gel. Linear plasmid on the other 
hand will cause more frictional resistance and therefor move slower on the gel, resulting in 
appearance at higher kB than supercoiled plasmid on the gel (116). The concentration of the 




Figure 4.2: Electrophoresis in 1% agarose gel stained with GelGreen. The band shift indicates linearization of 
the vector pETNKI-his-3C-LIC-amp. The first line is the ladder, the second line is the vector without kpn1-
treatment and the third line is the knp1-treated vector.  
 
The amplified genes and vectors were separately treated with T4 DNA polymerase to create 
single stranded overhangs, mixed together followed by an annealing step. Mixtures were then 
transformed into competent cells, TOP10, and plated on agar plates containing ampicillin. 
Colonies from the plates were analyzed with colony PCR to determine the presence or 
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Figure 4.3: Electrophoresis in 1% agarose gel stained with GelGreen. Result from colony PCR. FHMP138 and 




Figure 4.4: Electrophoresis in 1% agarose gel stained with GelGreen. Result from colony PCR with FHMP1 
presented on the gel, while the rest of the bands are empty vectors or non-clear cloning result.  
 
4.1.3 Sequencing 
Positive colonies from the cloning process were sent for sequencing. The sequence results 
received back were positive for FlHb1, FlHb138 and NR1. The sequence results received 
back were compared with the sequences in Figure 2.5 and 2.6 using SnapGene® Viewer and 
ExPASy translate tool (104).  
 
The cloning and sequence result for the FlHb25 construct and NR2 were negative.   
 
4.2 Protein expression  
4.2.1 Expression of flavohemoglobin assemblage A with pET14b-gFlHb 
During the expression of FlHb (GL50803_15009) with the vector pET14b-gFlHb, aliquots 
from different time intervals were collected for analysis using SDS-PAGE. Samples from 
both soluble (supernatant) and mixed soluble and insoluble (lysate) fractions at each time 
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interval are presented on the SDS-PAGE (Figure 4.5). The SDS-PAGE shows clear, thick 
bands at approximately 54 kilodalton (kDa). The bands in Figure 4.1 indicate that 17 hours of 
incubation was enough for the E.coli Rosetta cells to express the protein well.  
 
Figure 4.5: SDS-PAGE gel showing protein expression of pET14b-gFlHb. First line is the ladder, second and 
third one is at time 0 respectively lysate (L) and supernatant (S) sample. Fourth and fifth lines respectively show 
lysate and supernatant after 17 hours. Sixth and seventh lines respectively show lysate and supernatant after 24 
hours and the eight and ninth respectively show lysate and supernatant after 2 days.  
 
4.2.2 Expression of flavohemoglobin assemblage A with pJ401-gFlHb 
FlHb (GL50803_15009) with the vector pJ401-gFlHb was expressed in both LB and TB 
(101) medium (all other conditions were the same as for pET14b-gFlHb) to find out which 
medium that would give the best expression. The protein is expressed at approximately 54 
kDa (Figure 4.6). FlHb is presented both in the lysate (Figure 4.6) + and – from the SDS-
PAGE (Figure 4.7) is from the same original plasmid, but those who are marked with + was 
sequenced in advance of the expression. From the SDS- PAGE (Figure 4.6) it looks like TB is 
the best choice for expressing FlHb in Rosetta (DE3).  
 
Bands corresponding to the right size on the SDS-PAGE gel were sent for PMF, and the result 
confirmed that we had expressed the right protein.  
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Figure 4.6: SDS-PAGE showing samples collected during expression of pJ401-gFlHb in both LB and TB media. 
Samples are collected before IPTG-induction (0) and after IPTG-induction after 20 and 24 hours. All the 
samples are from the lysate. + is sequenced pJ401-gFlHb and – is non-sequenced pJ401-gFlHb.  
 
4.2.3 Expression of flavohemoglobin138 
FlHb138 was expressed using Rosetta (DE3) cells as host in TB media. Aliquots were taken 
right before IPTG induction (0 h), and after 17 h and 24 h after IPTG induction, for analysing 
using SDS-PAGE. Samples from both supernatant (soluble) and lysate (cell lysate containing 
both soluble and insoluble proteins) fractions at each time interval, are presented on the SDS-
PAGE (Figure 4.7). The protein is mostly represented in the lysate fraction (L), meaning that 
the protein might not be soluble in current buffer conditions or the cell lysis was not 
successful. The size of FHMP138 is 51 kDa with the His6-tag and the cleavage site attached 
to the protein, which fits well with the thickest, bands shown on the SDS gel (Figure 4.7).  
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Figure 4.7: SDS-page gel showing protein expression of FlHb138. First line is the ladder, second and third one 
is at time 0 respectively lysate (L) and supernatant (S) sample. Fourth and fifth lines respectively show lysate 
and supernatant after 17 hours. Sixth and seventh lines respectively show lysate and supernatant after 24 hours.  
 
4.2.4 Expression of nitroreductase 1 
Expression test for NR1 was done in two different ways. In both cases, aliquots from different 
time intervals were collected for analysis using SDS-PAGE. Samples from the expression 
with Rosetta (DE3) cells in TB media, is shown on the left hand side from the SDS gel 
(Figure 4.8). Samples were collected right before IPTG induction (0 hours), after 17 hours 
and after 24 hours. The protein is expressed after 17 hours, but a higher expression level is 
reached after 24 hours. The protein is mostly in the lysate fraction, meaning that the protein is 
not that soluble in this case. NR1 size is 32 kDa. From the SDS gel (Figure 4.8) the thickest 
bands at approximately 35 kDa represents the NR1.  
 
Samples from the expression in autoinduction media (ZYM-5052 autoinduction media) (109)  
is shown on the right hand side from the SDS-gel (Figure 4.8). The protein was expressed 
during the weekend (for 64 hours), and is presented mostly in the lysate fraction in this case 
as well.  
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Figure 4.8: SDS-PAGE showing samples from expression of NR1, with IPTG induction on the left hand side and 
with autoinduction on the right hand side. L = lysate and S=supernatant. Samples from IPTG induction were 
collected right before IPTG was added, which is set to time 0, and then after 17 and 24 hours. Samples from 
autoinduction were collected right before the temperature was lowered, which is set to time 0, and then after the 
weekend (64 hours). The protein of interest, NR1, is shown as thick blue bands at approximately 34 kDa.  
	  
Bands corresponding to the size of the thickest bands from Figure 4.8 were sent for PMF. 
Results from PMF confirmed that the expressed protein was NR1.  
 
4.3 Purification  
4.3.1 Affinity purification of flavohemoglobin from assemblage A  
His-tag purification using Ni-NTA column was successful for both the pJ401-gFlHb and the 
pET14b-gFlHb vector. The Ni-NTA resin turned from a blue color to a reddish brown color 
when the protein bound to the resin. The red color is likely to origin from the heme bound in 
the protein. The eluted protein solution had an intense reddish brown color. Samples from the 
purification steps were collected and are shown on the SDS-PAGE (Figure 4.9). The first line 
represents the lysate (L), the second line represents the supernatant (S), the third line 
represents the flow trough (FT) and the forth line represents the elute (E). FlHb is presented in 
all of the lines, but it is the only one presented in E. FlHb is shown as a thick band at the SDS-
PAGE at approximately 54 kDa.  
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Figure 4.9: SDS-PAGE showing samples from the steps during His-tag affinity purification of FlHb assemblage 
A. L=lysate, S=supernatant, FT=flow trough, E=elute.  
 
4.3.2 Affinity purification of flavohemoglobin138  
For the His-tag affinity purification on FlHb138, the Ni-NTA resin turned from a blue color to 
a red color similar with FlHb from assemblage A. The samples collected from the purification 
steps are shown on SDS-PAGE (Figure 4.10). In this case, the elute was not as pure as for 
FlHb assemblage A. FlHb138 is presented as the thickest band in all of the lines, except wash 
number four (W4), at approximately 55 kDa from the gel (Figure 4.10) The size of FlHb138 
is approximately 54 kDa. 
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Figure 4.10: SDS-PAGE showing samples from the steps during His-tag affinity purification of FlHb138. 
L=lysate, S=supernatant, FT=flow trough, W=wash, E=elute. FT1 was collected and run trough the column, 
resulting in FT2. The column was washed four times before the protein was eluted.   
 
4.3.3 Affinity purification of nitroreductase 1 
His-tag affinity purification was used to purify NR1. The samples collected from the 
purification steps are shown on SDS-PAGE (Figure 4.11). The size of NR1 is 32 kDa without 
the His-tag and cleavage site on. The size of the protein will be larger because the His-tag and 
the cleavage site are attached to the protein. NR1 is presented at approximately 45 kDa on the 
SDS-PAGE (Figure 4.11).  
 
 
Figure 4.11: SDS-PAGE showing samples from the steps during His-tag affinity purification of NR1. L=lysate, 
S=supernatant, FT=flow trough, W=wash, E=elute. FT1 was collected and run trough the column, resulting in 
FT2. The column was washed three times before the protein was eluted.  
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4.3.4 Size exclusion chromatography 
SEC was performed with FlHb from assemblage A and from assemblage B (with Superdex™ 
200 increase 10/300). The elution profiles from both constructs are shown in Figure 4.13. The 
green line represents FlHb from assemblage A and the blue line represents FlHb138 from 
assemblage B. The two highest peaks represent FlHb from each assemblage. For FlHb 
assemblage A (green line), a smaller peak was eluting earlier than the main peak. Fractions 
from both the small peak and the main peak were collected in separate tubes. The fractions 
from the smaller peak were colorless, while the fractions from the main peak had a red color. 
The red color was however weaker than the protein solution had before SEC.  
 
 
Figure 4.12: Elution profiles from SEC showing the elution profile from FlHb138 (blue) and elution profile from 
FlHb assemblage A (green) at UV280. Absorbance (mAU) is shown in a relative scale to fit the two peaks.  
 
The fractions from the two peaks from assemblage A (green line in Figure 4.12), which were 
close to each other were collected and analyzed on SDS-PAGE. The bands representing each 
fraction were sent for PMF. Results from PMF, showed that the two bands were the same 
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4.4 His-tag cleavage 
The His6-tag was not cleaved off with neither of the proteases TEV nor thrombin for FlHb 
from assemblage A. The cleavage of FlHb138 assemblage B with 3C protease seemed to 
work. The cleavage is shown at SDS-PAGE (Figure 4.13). There is small shift in the bands 
comparing the band representing FlHb138 sample without 3C protease and the band 
representing FlHb138 with 3C protease. The cleaved sample seems to be a few kDa smaller 
than the original FlHb138.  
 
 
Figure 4.13: SDS-PAGE showing His6-tag cleavage with 3C protease. The first line is the ladder, the second line 
is FlHb sample without 3C protease and the third line is FlHb with 3C protease.  
 
4.5 Characterization of flavohemoglobin assemblage A 
4.5.1 Light scattering  
SEC-MALS was used to measure the molecular weight. The light scattering (LS) curve from 
SLS and the estimated molecular weight (Mw) are shown in Figure 4.14. The curve shows 
three peaks, whereas the first peak is probably aggregates, the second tiny peak (bump) is the 
colorless fraction and the third high peak is the FlHb. From the measurement, the molecular 
weight of FlHb was estimated to be 59.6 kDa. The theoretical Mw (calculated from 
ProtParam) Mw is 54.2 kDa with the His6-tag and cleavage site attached to the protein. This 
shows that FlHb elutes as a monomer. Mw is shown as a red line in Figure 4.14.  
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Figure 4.14: Curve from SEC-MALS, light scattering signal vs. time (min.). Estimated molecular weight for 
flavohemoprotein marked with red thick line (5.96x104 g/mol). 
 
The second experiment of SEC-MALS was performed by Erik Hallin at Diamond before 
SAXS. The measurement was done from only affinity purified sample to have higher amount 
of the colorless variant of FlHb to see if the two species have different properties. The LS 
curve is presented in Figure 4.15 together with the estimated Mw. The two peaks in the curve 
represent respectively the colorless and the colorful variant of FlHb from assemblage A. The 
estimated Mw for the colorless variant of FlHb is shown as a red line in Figure 4.15. It was 
estimated to 128.2 kDa. The estimated Mw for the colorful variant of FlHb is shown as a 
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Figure 4.15: Light scattering curve from SEC-MALS in relative scale. The first peak represents the colorless 
FlHb from assemblage A, and the second peak represents the colorful variant of FlHb from assemblage A. The 
red line represents the Mw for the colorless variant (1.28x105 g/mol), and the green line represents the Mw for 
the colorful variant (6.27x104 g/mol).  
 
4.5.2 Circular dichroism  
CD was performed with FlHb from assemblage A. The CD spectrum of FlHb is shown in 
Figure 4.16. The shape of the curve illustrates the secondary structure of the protein. In this 
case it illustrates a combination of α-helices and β-sheets. CD was performed with changes in 
temperature as well, to estimate the Tm. This is shown in Figure 4.17. There is a transition 
between the line at 40 °C (orange) and 45 °C (blue) in Figure 4.17. This indicates that the Tm 
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Figure 4.16: CD spectrum of FlHb from assemblage A.  
Figure 4.17: CD spectra with melting curve of FlHb from assemblage A. The melting point is around 45 °C 
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Due to the observation of two variants of FlHb (colorful and colorless), samples from each of 
the variant were run on CD to compare the spectra. The spectra are shown in Figure 4.18. The 
spectrum of colorful FlHb is shown in blue, and the spectrum of colorless FlHb is shown in 




Figure 4.18: CD spectra of colorless (red) and colorful FlHb (blue) FlHb.  
 
 4.5.3 Thermoflour  
The melting curve representing each well from the salt/buffer screen (Table 3.3) is presented 
in Figure 4.19. Each color line represents the Tm for each condition in each well. There were 
no large differences in the Tms for each of the conditions. The melting temperature was 
between 42 °C and 44 °C in most of the conditions from Table 3.3. But the wells G9, G10, H9 
and H10 (see Table 3.3) had slightly higher Tm (48 °C) values compared to the other wells. 
These wells had 20 mM buffer with pH 7.5, higher amout of salt (250-500 mM) and 10% 
glycerol. Based on these results, FlHb seems to be stable with higher concentration of salt and 
glycerol. We then decided to stay with the buffer (20 mM HEPES pH 7.5) we had used so far, 
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Figure 4.19: Melting curves from thermofluor. All conditions from the buffer/salt screen are represented in the 
figure showing that only minor changes were observed with this screening.    
 
4.5.4 Small angle X-ray scattering  
SEC coupled SAXS was performed with FlHb assemblage A (colorful and colorless variants). 
Collected SEC-SAXS frames were processed using a script written by Erik Hallin. The buffer 
region is defined from frames 50 to 150 (Figure 4.20). The buffer scattering was subtracted 
from the sample to obtain the protein scattering curve. The frames representing each peak of 
the protein were defined based on radius of gyration (Rg). Rg is linear in the regions of the 
frames. The first peak of the two highest peaks in Figure 4.20 is the colorless variant of the 
FlHb. SAXS data from this peak are defined from frames 338 to 348. The Rg values are linear 
for these frames shown in Figure 4.20 with red dots. The second peak of the two highest 
peaks in Figure 4.20 is the colorful variant of FlHb. SAXS data from this peak are defined 
from frames 367 to 378. The Rg values are linear for these frames shown in Figure 4.20 with 
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Figure 4.20: SEC-SAXS profile of FlHb containing two variants. The measured intensity is represented in the 
function of collected frames. The colorless variant is presented as the first peak of the two highest peaks close to 
each other, with its linear Rg region presented as red dots. The colorful variant is presented as the second peak 
of the two highest peaks close to each other, with its linear Rg region presented as green dots.   
 
The scattering data from the colorless and the colorful variants are presented in Figure 4.21. A 
in Figure 4.21 is the SAXS curve (log plot) for the two variants. B in Figure 4.21 is Kratky 
plot of the colorful variant of FlHb (Kratky plot of the colorless variant looks similar). The 
curve has a bell-shape, which indicates that the protein is globular. 3D models based on the 
scattering data were created using GASBOR and the images were made using PyMol. The 
models of the overall shape of both the colorless and the colorful variants are shown aligned 
in Figure 4.21. The colorful variant has a more closed and globular shape compared with the 
colorless variant, which has a more open shape and the size seems to be larger. The Mw 
estimated to 94.7 kDa for the colorless variant and 53.6 kDa for the colourful variant, based 
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Figure 4.21: SAXS data from colorless and colorful variants of FlHb assemblage A. A) Logarithmic plot 
showing intensity in function s (inverse angstroms), of SAXS curved (raw data) with fitted data from colorless 
(turquoise raw data and yellow fitted line) and colorful (red raw data and blue fitted line) variants of FlHb. The 
plot is made with Primus. B) Kratky plot of colorful variant of FlHb (raw data is red and the line for averaged 
data is blue). The plot is made with Primus. C) Aligned overall shape of colorless (grey) and colorful (red) 
variants of FlHb. The model is made with GASBOR and created with PyMol.  
 
Table 4.3: Results from Guinier and distance distribution analysis using Primus, molecular 
weight was estimated based on the porod volume.  
 Colorless FlHb Colorful FlHb 
I0 0.11 0.11 
Rg (Å) 35.46 28.42 
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4.6 Protein crystallization  
Protein crystals containing the characteristic reddish color of FlHb were not observed during 
crystal screening trials. Most of the conditions were prone to precipitate although lower 
concentrations of protein were tried in the crystallization experiments as well. However, 
square, transparent microcrystals were formed under the conditions presented in Table 4.4 
(using PACT-premier). The protein solution of FlHb from assemblage A was only purified 
with affinity chromatography in advance. The concentration of the protein solution was 11 
mg/mL. The microcrystals were colorless, but they were UV positive (see Figure 4.22) 
indicating them to be proteins. The microcrystals did not diffract when they were tested at the 
beam line P11 at DESY/PETRA III by Juha Kallio.  
 
Table 4.4: Conditions where microcrystals were formed. Protein and the well solution were 
mixed 1:1 and the drop size was 600 nL.  
Conditions in the protein solution Condition in the well from PACT-premier 
150 mM NaCl 0.2 M Na Sodium citrate (Na3Cit) 
20 mM HEPES pH 8 20 %w/v PEG 3350 
1 mM TCEP 0.1 M BIS-TRIS pH 8.5 
5 % glycerol  
 
 
Figure 4.22: UV Fast image of microcrystals from FlHb from assemblage A (11 mg/mL). Image from ROCK 
IMAGER®.  
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5. DISCUSSION  
	  
FlHb from assemblage A was successfully expressed in E.coli and purified with both affinity 
purification and SEC. From the SEC elution profile, two variants of FlHb, one containing 
heme and one without heme, were observed. FlHb from assemblage A was characterized with 
CD, LS and SAXS. FlHb seems to consist of both α-helices and β-sheets as predicted. A 
solution 3D model for each of the variants was obtained by SAXS. The heme-containing 
(active) variant seems to be monomeric and have a globular shape, while the heme-less 
variant has a more open structural shape with a doubled size compared to the active variant. 
Stability tests were performed with thermofluor and CD, indicating that the Tm of FlHb is 40-
45 °C and the protein is probably more stable in higher salt concentrations and addition of 
glycerol.  
 
Two constructs of FlHb (FlHb1 and FlHb138) and NR1 from assemblage B were successfully 
cloned into pETNKI-his3C-LIC-amp vectors using competent cells. Further, FlHb138 and 
NR1 were for the first time expressed using E.coli as host cells, and purified with affinity 
purification. In addition, FlHb138 was purified with SEC. The His6-tag was successfully 
cleaved off with 3C protease for FlHb138.  
 
An overview of what have been done with each of the proteins is presented in Figure 5.1. The 
discussion is presented in a chronological order to get a better overview.  
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Figure 5.1: An overview of what have been done with each of the proteins in this study.  
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5.1 Genes used in this study   
5.1.1 Flavohemoglobin 
FlHb from assemblage A (GL50803_15009) is the reference genome of FlHb. This gene 
sequence is used in other studies as well (53, 117-119). The sequence of FlHb from 
assemblage B (GSB_151570) is from clinical isolates, which infects humans, and not from 
the reference genome used in the previous studies. FlHb from assemblage A and the construct 
FlHb138 from assemblage B have the same number of AA. They are aligned in Figure 5.2. 
The sequence identity is 72 %. The sequences are quite similar, indicating that their functions 
also should be similar. The structure and role of the long extended N-terminus of FlHb from 
assemblage B remains to be elucidated for the further research.  
 
Figure 5.2: Amino acid alignment of FlHb from assemblage A (ass. A) and FlHb138 from 
assemblage B (ass. B).  
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5.1.2 Nitroreductases  
The gene sequence of NR1 (GSB_153178) and NR2 (GSB_22677), are from clinical isolates 
obtained from infected humans, and not from the reference genome. The NRs described in 
this study are hypothetical proteins, meaning that their existence have been predicted (in this 
case from clinical isolates), but there are lack of evidence that they are expressed in vivo 
(120). NR1 has now been expressed in this project.  
 
5.1.3 Other metronidazole activating and O2 detoxifying enzymes have been 
characterized  
PFOR and TrxR are presented in Figure 1.3 and have shown to activate MTZ. These two 
enzymes have been characterized in previous studies. The crystal structure of TrxR from 
Giardia has been solved (PDB code 5M5J) (121). TrxR (strain ATCC 5803, WB clone C6) 
was expressed in E.coli. In silico studies with MTZ covalent bound TrxR was performed. 
From their results, it seems like MTZ has TrxR as the primary target (121). PFOR has been 
characterized (44), but the crystal structure needs to be solved. PFOR was expressed 
anaerobic in Giardia trophozoites, purified and the activity was detected (44).  
 
NADH oxidase and FDP (1.4) have shown play a major role in O2 detoxifying in Giardia. 
NADH oxidase (GL50803_33769) has been expressed in E.coli, purified and biochemically 
characterized (122), but a deeper understanding of its structural and functional properties are 
required. For FDP on the other hand, the structure has been solved (PDB code 2Q9U) (123). 
The protein was expressed using E.coli. Their results show that FDP scavenge O2 more 
efficiently than NO (123). One study (124) demonstrated that PFOR are involved in MTZ 
activation and resistance, TrxR reduces MTZ and a decrease in NADH oxidase FMN 
reduction activity was found.  
 
More research is needed for the proteins that already have been characterized and the proteins 
used in this study, to get the full picture of how Giardia is able to detoxify MTZ, NO and O2.  
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5.2 Cloning 
The cloning was successful for both the one-step SLIC method (100) and the original T4 
DNA polymerase exonuclease treatment from ACEMBL (98). The one-step SLIC would be 
beneficial with respect to time, and may be used in future studies.  
  
All preparation before PCR run was done under normal laboratory conditions. This could lead 
to contaminations from the environment. The cloning of the FlHb25 construct of FlHb and the 
constructs of NR2 was not successful. There may be several reasons for the unsuccessful 
cloning, and contaminations from the environment may be one of them. Another reason could 
be low concentrations of the constructs. Table 4.2 shows that the concentrations of the 
amplified genes after gel purification with PCR cleaning kit were low, but that applies to all 
of the constructs.  
 
5.3 Expression  
	  
The FlHb pellets from expression using pET14b-gFlHb were chosen for structural studies. 
This leaky vector has slower expression rate for the protein than the vector that require IPTG 
induction, resulting in the heme synthesis to better keep up with the expression rate. This 
leads further to more heme-containing FlHb (125).  
	  
5.3.1 Time, temperature and obtained protein concentration 
Expression of FlHb (GL50803_15009) with the vector pET14b-gFlHb seemed to best after 17 
h from Figure 4.5. pET14b-gFlHb is a leaky vector, which can be favourable to express 
properly folded proteins and especially for heme synthesis to keep up with the protein 
expression (126). Lower protein concentrations, and slower rates of expression could also 
improve transcription and translation and favour proper folding of the proteins (126). FlHb 
seemed to be properly folded in this case, even if the time of incubation was 42 h, but the 
level of expressed FlHb was highest after 17 h. The expression could have been stopped after 
17 h to get a better yield of the protein, even if the yield was high after both 24 h and 42 h. 24 
h was chosen for larger scale expression because the difference between 17 h and 24 h was 
minimal. Better yield could also have been obtained by lowering the temperature (127), as a 
reduction in expression temperature is associated with increase in soluble proteins (128). 
Lower temperatures could have been used for the expression of FlHb138 and NR1, because 
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they were mostly presented in the lysate fractions of the samples collected during expression 
tests (Figure 4.7 and 4.8). This was not done, because of time limitation of the project. It 
should however be tried in further research.   
 
5.3.2 Expression with addition of IPTG 
The expression for pJ401-gFlHb failed the first times. The cells did not express FlHb. The 
cells were growing rather slowly while incubating and the pellets did not turn pink like they 
did for pET14b-gFlHb, and no clear thick bonds were seen on the SDS-PAGE gel. The 
difference between the expression of FlHb using pJ401-gFlHb compared with pET14b-gFlHb 
was the addition of IPTG. IPTG from a new stock for pJ401-gFlHb was tried. After this, 
expression of FlHb using pJ401-gFlHb worked well as presented in the result section (Figure 
4.6).  
 
The IPTG concentration used in this study was 1 mM. 1 mM IPTG has been used to express 
FlHb in other studies as well (129, 130). Also as low concentration as 0.1 mM have been used 
to express FlHb (131). The optimal concentration of IPTG for induction can vary from protein 
to protein. If the concentration is too low, the expression will result in low levels of expressed 
protein. If the concentration is too high, the protein can aggregate and be insoluble (132). 
Different concentration intervals between 0.1 mM and 1 mM IPTG should be tried during 
expression of new FlHb constructs in further studies to find the optimal expression conditions.  
 
5.3.3 Cell lysis 
In this project, the pellets collected from expression were lysed with lysozyme (0.1 mg/mL) in 
addition to sonication. Lysozyme is an enzyme with the ability to break the bacterial cell 
walls (133). High concentrations (2.5 mg/mL) of lysozyme will result in a decreased 
lysozyme activity, meaning less lysed cells (134).  
 
Sonication uses ultrasonic waves to generate localized areas of high pressure, resulting in cell 
break down (135). Sonication can lead to unfolding and aggregation of the proteins because 
of the heat generated and the mechanical forces applied (136). To avoid high temperatures, 
the sonication was performed while the bacterial solution was kept on ice. The combination of 
lysozyme and sonication seemed to work well for the expressed FlHb from assemblage A and 
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B. The smaller samples collected during expression and analyzed on SDS-PAGE were only 
sonicated before analyzed with SDS-PAGE, because the samples were so small (1 mL). For 
FlHb from assemblage A, the protein was present with both samples before (L) and after 
sonication (S) (see Figure 4.5). For FlHb138 (Figure 4.7) and NR1 (Figure 4.8) the proteins 
were mostly represented in the samples that were not sonicated. This can be a result of poor 
solubility in the condition used under the expression process or it can be a result of poor 
sonication. Alternative lysing methods should also be tested in future studies.  
 
5.4 Purification  
5.4.1 Affinity purification – binding to the resin  
Purification using Ni-NTA affinity chromatography is a straightforward method. The purified 
product was pure for FlHb assemblage A (Figure 4.9), but both FlHb138 (Figure 4.10) and 
NR1 (Figure 4.11) had some impurities in the purified product. The impurities from NR1 
were sent for PMF, and were recognized as enzymes (transferase/decarboxylase) from E.coli. 
E.coli was used as host cell for the expression of both FlHb and NR1, but it is not common 
that host cell proteins have histidine residues on their surfaces that can unspecifically bind Ni-
NTA, especially when the expression level of the target protein is low (137). Some proteins of 
the host bind weakly to the resin, but can be removed by including a low concentration of 
imidazole (20 mM) for competitive binding (137). Although this was attempted, the 
impurities were still there. One possible explanation can be that proteins from the host cell 
can potentially cluster on the surface of the folded protein and mimic a His-tag, or proteins 
with natural ion binding sites will also bind to the resin and affect its selectivity. In this cases, 
host impurities will be co-eluted with the protein of interest (137).  
 
In all the cases of using Ni-NTA affinity chromatography, the protein was in the flow through 
and in some cases also in the washing buffers. This indicates that not all of the protein was 
bound to the resin, even though the Ni-NTA resin has a high capacity (60 mg of protein per 
mL of resin) according to the manufacture.  
 
To reduce unspecific binding, other metal affinity resins could also be tested. For example 
resin loaded with cobalt requires two consecutive histidines to meet the requirements of metal 
coordination and that increases the specificity to the his-tagged proteins (138).   
          	  	  
	   75	  
5.4.2 Affinity purification – chemical environment 
Different salt concentrations and pH were tested for NR1. It is common to use NaCl (0.3-0.1 
M), and a slightly basic pH (137). NaCl is added to minimize ionic interactions between the 
protein and the resin (137). A reducing agent is added as well (0.5 mM TCEP) to prevent 
oxidation of the protein and to keep the surface exposed cysteine free of forming intra 
molecular disulfide bonds (139). In the first test purification of NR1, lysis buffer 1, wash 
buffer 1 and elution buffer 1 with pH 7 were used (see appendix 1). This was not successful. 
The second and third test purifications were done simultaneously with respectively lysis 
buffer 2, wash buffer 2 and elution buffer 2, and lysis buffer 3, wash buffer 3 and elution 
buffer 3. The buffers for the second purification test had an increased salt concentration (see 
appendix 1) and a pH of 5. The theoretical isoelectric point (pI) value of NR1 is 6.25. When 
the pH has the same value as the pI, the protein has a net charge of 0 (56). The selected pH 
during the purification should therefor be at least one unit above or under the pI of the protein 
to keep the protein charged (140, 141). Increasing the salt concentration will increase the 
ionic strength and therefor increase the solubility of the protein and prevent aggregation 
(142). The third test purification had the same increased salt concentration, but the pH was 
adjusted to 8.5. The purification with a pH of 5 seemed to be better for the solubility, but the 
pH is not ideal for the resin (according to the manufacture), and a last attempt using pH 6 was 
performed (all other conditions were the same as for the second purification). This was 
unsuccessful. Maybe due to the theoretical pI of 6.25 as the protein should be less soluble 
close to its pI value because the protein is not charged and therefore less soluble.  
 
Suitable chemical environment should be extensively screened during proper solubilization 
screening were different compositions of lysis buffers are used in parallel, to see what kind of 
conditions could possibly affect the solubility of the protein sample.  
 
5.4.3. Freeze the purified protein 
After purification of the protein of interest, it is important to store the protein solution in a 
proper way. The storage method of choice depends on the stability of the protein and the 
storage time (143). For short term (up to 24 h) storage, the protein solution can be kept at 4 
°C. If the protein is stored for weeks or months, it is necessary to freeze the protein (-20 °C). 
And further, if the protein solution is stored for even longer terms (months to years), it is 
recommended to store the protein at -80 °C (143). 
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In this project, the protein solution of FlHb assemblage A, was first stored at -20 °C. When 
the protein solution later was thawed, the proteins were precipitated. This means that FlHb 
cannot be stored in the freezer, and other storage options for the proteins were needed. Other 
storage options for the proteins is to lyophilize the proteins and then store them at either 4 °C 
or -20 °C, but not all proteins are stable during freeze-drying processes (144). Another option 
would be to store them in a solution consisting of 50 % glycerol at -20 °C. Snap freezing with 
nitrogen, with addition of 5-50 % of glycerol and storage at -80 °C could also be an option 
(143). Snap freezing with liquid nitrogen with addition of 5 % glycerol was chosen in this 
project and was successful.  
 
FlHb protein solutions with different concentrations (2-18 mg/mL) and volumes (200-500 µL) 
were stored at -80 °C in separate effendorf tubes. When thawing the protein solutions later, 
the protein solutions with the highest concentration (18 mg/mL) were precipitated. Diluted 
protein solutions are more prone to inactivation and loss of protein, and therefore protein 
solutions in more concentrated form is recommended (145). Based on the observation that 
protein solutions with higher concentrations were precipitated, we diluted the following 
protein solutions to lower concentrations (5-10 mg/mL), to allow storage. Smaller volumes 
(200 µL) were favourable in order to make the freezing process with liquid nitrogen faster.  
 
5.5 His-tag cleavage  
The His6-tag of FlHb138 was successfully cleaved off using 3C protease. In this case, the 
cleavage site is exposed to and recognized by the protease, resulting in a successful cleavage.  
 
For the flavohemoprotein from assemblage A, the advantage of using pJ401-gFlHb compared 
with pET14b-gFlHb is that the His6-tag can be cleaved off using TEV protease. TEV is a 
widely used protease to cleave the His6-tag due to its high specificity (146). In theory this 
enzyme works well for cleaving the tag off. This was not the case in this project. Using 
pET14b-gFlHb, the His6-tag can be cleaved off using thrombin. Cleavage with thrombin is 
not as specific as for TEV, and the cleavage can occur at other sequence sites in the protein 
(147). In this project it seemed that also the thrombin cleavage failed. Considering that the 
cleavage trials in both cases failed, the explanation may be related to the folding of FlHb 
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construct. The cleavage site may be buried or blocked due to the protein folding, so that the 
site recognized by protease is not accessible. 
 
Cleavage of small affinity tags such as His6 is not required to grow protein crystals, and may 
not affect the crystallization process (148). Cleavage of the His6-tag is still wanted, because it 
is not a part of the original protein if interest.  
 
5.6 Colorful and colorless variants of flavohemoglobin from assemblage A 
The two variants of FlHb from assemblage A, were first observed from the SEC elution 
profile. The two peaks were both conformed to be FlHb from PMF. Fractions from the main 
peak had a reddish brown color, while fractions from the smaller peak were colorless. The 
reddish brown color comes from the heme bound inside the protein. Considering the one 
variant of the protein, is missing the reddish brown color, it is likely that the heme is not 
bound to this variant. The heme-containing one, is the one if interest, because it is the active 
FlHb.  
 
From the SAXS model (Figure 4.21), the overall shape of the two variants indicates that the 
colorless variant had a more open structure compared to the colorful variant. The colorful 
variant had a globular, more closed structure. The FlHb structure from Alcaligenes eutrophus 
is given in Figure 1.5, where the heme pocket is illustrated. It is likely that heme is bound at 
the approximately same place in the structure of FlHb from Giardia. Based on the structural 
differences between the colorful and the colorless variant, and the lack of heme in the 
colorless variant, one suggestion would be that the heme keeps the structure more globular. 
When the heme is released, FlHb might undergo conformational changes. Based on our 
results we can suggest that colorless variant might form a dimer in solution. From the Mw 
estimated from both SAXS and SEC-MALS, it seems like the size of the colorless variant is 
doubled compared to the colorful variant. One explanation of the doubled size can be that two 
protein molecules from the colorless variant are bound, forming a dimer. One possibility is 
that when the heme is released, and the structure opens up, it might require another FlHb 
molecule to bind and cover the exposed more hydrophobic surface. Probably only the colorful 
variant is active of which would be requested for the further research.  
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5.6.1 Addition of heme  
The color change of FlHb has been seen in other studies as well from other organisms, caused 
by loss of both cofactors; heme and FAD (54, 130, 131, 149). Heme reduction may be 
achieved by an associated FAD-containing reductase domain (149). The heme content of 
FlHb can be increased by addition of heme and FAD before gel filtration (54). If the heme is 
lost during gel filtration, reconstitution of heme and FAD after purification may help to obtain 
more heme bound to FlHb (130).  
 
Heme was not added in this project due to lack of time to find a suitable protocol for this. 
Heme is challenging to use because of its solubility. Heme is soluble in diluted ammonia, 
NaOH and other strong organic bases (150). By dissolving heme in such a strong base, it will 
probably change the chemical environment of the protein even with small additions of heme. 
Another problem with heme is that it is expensive and the amount of heme required to keep 
the heme inside FlHb is not known. A third problem with heme is that we do not know if it 
will get stuck in the column during gel filtration or affect the purity of the protein sample. 
One possibility of doing this would be to add the heme before gel filtration followed by buffer 
exchange and then gel filtrate.  
 
5.7 Exposure to oxygen 
 
All the experiments in this project were performed under aerobe conditions, while Giardia is 
a microaerophilic parasite. In reality, giardial FlHb and NRs would not be exposed to the 
same amount of O2 as during the laboratory work in this project. Protein expression, 
purification and structural studies are more challenging to perform under anaerobe conditions, 
and were therefore not done in this project. FlHb detoxifies NO using O2 as a co-substrate 
(54). FlHb from E.coli detoxifies NO in aerobic conditions, but not in anaerobic conditions 
(151). Based on this, and the fact that FlHb was expressed and characterized under aerobe 
conditions it does not look like O2 is harmful to the protein. But it would be of interest to try 
to use anaerobic growth conditions in addition to anaerobic purification steps, to compare the 
proteins under each condition, to see if O2 has an effect on the protein. Activity assays would 
also be of interest to perform for aerobic and anaerobic expressed FlHb, to compare the 
enzymatic activity with or without the absence of O2.  
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5.8 Crystallization 
5.8.1 Optimization of crystal conditions 
Screening for crystallization conditions was done with different concentrations of FlHb from 
assemblage A. The concentration varied from 5-12 mg/mL, with minimal change in the 
protein behavior in the corresponding drops on the plate. The proportion of precipitating 
drops and clear drops were quite similar for each of the concentration variations of the 
protein. When the drops are clear, it means that the protein-solvent interactions are stronger 
than the protein-protein interactions (152). When the drop on the other hand is producing 
precipitants, it means that the protein-protein interactions are stronger than the protein-solvent 
interactions causing the solubility of the protein to decrease too much (152). Crystals are 
formed when the concentration of protein is increased until the solubility is exceeded and the 
protein comes out of solution (56).  
 
Once some crystals are formed, the optimization of the crystal conditions can begin (93). We 
obtained some microcrystals that were UV-positive (Figure 4.22), but unfortunately the 
microcrystals did not diffract. Crystals were grown under the conditions presented in Table 
4.4. Each of the factors from the Table 4.4 could be systematically varied to find the optimal 
crystallization condition for this hit. Although it might not be worth of optimizing because the 
crystals were colorless, and were probably not formed from the active FlHb.  
 
5.8.2 Homogeneity  
Homogeneity is important for successful crystal growth. The protein solution must be purified 
to homogeneity or as close as possible to homogeneity (94). The observation of FlHb from 
assemblage A, separating into two different variants during SEC, indicates that the FlHb 
protein solution is not homogeneous. Even though fractions from the colorful peak from the 
elution profile were collected and used for crystallization trials, it seems like the protein is not 
stable over time. Crystallization trials were set up for both the colorful and the colorless 
variant of FlHb from assemblage A with the same conditions for both variants. The 
crystallization set up was done after SEC to separate the two variants. Resulting in no 
crystals. By separating the two variants, it is likely that the two separate protein solutions 
would be closer to homogeneity, than combining the two variants. Reconstitution of heme and 
FAD after purification may result in a homogenous solution (130). 
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5.8.3 Obtained flavohemoglobin crystals in literature   
In the publication of crystallization of FlHb from Alcaligenes eutrophus (64) they describe the 
crystals as yellow-brown colored with a needle-shape. The crystals were formed in 18 °C 
under the crystallization conditions: 14 % PEG3350, 0.2 M NaCl and 0.05 M sodium citrate, 
pH 5. In a master thesis from University of Oslo (130) they were able to grow crystals of the 
active FlHb from Bacillus cereus. The crystals formed were red or orange needles under 
various conditions in room temperature. The crystals did however not diffract under X-ray. 
Based on these two papers, it is likely to suggest that the crystals from FlHb from Giardia 
should be colorful and have a needle-shape. Our obtained microcrystals were much smaller, 
square and colorless (transparent) compared to the FlHb crystals obtained in the literature. 
Based on this, it is likely that our microcrystals were not formed by FlHb, but by something 
else. The microcrystals might be formed by precipitants.  
 
6. CONCLUSION 
6.1 Flavohemoglobin  
 
FlHb is a NO detoxifying enzyme found in Giardia. Both the full length (FlHb1) of FlHb 
from assemblage B and the construct (FlHb138) corresponding to FlHb from assemblage A, 
were successfully cloned into competent E.coli cells using pETNKI-his3C-LIC-amp as a 
vector and the method SLIC. FlHb138 was further expressed in Rosetta (DE3) cells in TB 
medium.  
 
FlHb from Giardia assemblage A was received in two different vectors (pJ401-gFIHb and 
pET14b-gFlHb). The protein was expressed in E.coli and purified. From the SEC elution 
profile, it was observed two variants of FlHb, one containing heme and one without heme. 
FlHb was characterized with thermofluor, CD, SLS and SAXS. The structural studies gave 
the possibility to compare the two observed variants of FlHb. From the structural studies it 
seems like the heme-less variant has a more open structural shape and behaves as a dimer 
compared to the heme-containing active variant, which is monomeric and has a closed, 
globular shape.  
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To obtain more information about its function, it would be desirable to form crystals with 
high resolution. No relevant protein crystals were obtained in this study, and new trials to 




NR1, are together with NR2, thought to be involved in the MTZ resistance mechanism of 
Giardia. NR1 was successfully cloned into competent E.coli cells using pETNKI-his3C-LIC-
amp as a vector and the method SLIC. The protein was expressed using Rosetta (DE3) as host 
cells in TB media, and purified. Little new information about NR1 was obtained in this study. 
NR2 was not straightforward to clone into the NKI system. Further research needs to be done 
for both of the enzymes, to obtain more information about their functions.  
 
7. FURTHER RESEARCH  
To be able to understand the MTZ resistance mechanisms of Giardia, proteins in the 
pathways that are thought to play a role in this mechanism needs further investigations. 
Characterization of FlHb, NR1 and NR2, which are important in these pathways, was started. 
By characterizing and solving the structure of the proteins, the structure-function relations of 
the proteins can be discovered. From the structure, more of the proteins functions could be 
obtained. This project resulted in no diffracting protein crystals, but initial expression and 
purifications were discovered for the FlHb and NR1, which may form the basis for further 
research. The expression and purification for assemblage B FlHb and NR1 need to be further 
optimized to obtain more soluble proteins and increasing the yields. In addition, some 
structural characterization was done for assemblage A FlHb. These results can be used in 
comparison when characterizing the FlHb from assemblage B. Further research to obtain the 
crystal structure of FlHb is needed. To obtain crystals from the active variant (heme-
containing), a way of adding heme to the protein solutions should be investigated to get heme 
to stay inside the protein. Additionally heme assays should be performed to quantify the heme 
concentration of FlHb and assess the ratio between concentrations of FlHb and heme. NADH 
oxidase activity could be performed to measure the enzyme activity of the FlHb after it can be 
stabilized to its active form.  
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No structural characterization was yet done for NR1 nor NR2 due to the time limit. This work 
should be continued in further studies.  
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          APPENDIX 1  
	   VII	  
 
Lysis buffer 1  
150 mM NaCl 
20 mM HEPES pH 7.5 
0.5 mM TCEP 




Wash buffer 1 
500 mM NaCl 
20 mM HEPES, pH 7.5 
0.5 mM TCEP 




Elution buffer 1 
150 mM NaCl 
20 mM HEPES, pH 7.5 
0.5 mM TCEP 




Gel filtration buffer 1 
150 mM NaCl 
20 mM HEPES, pH 8 
0.5 mM TCEP 
5 % glycerol  
 
 
Dialysis buffer 1 
150 mM NaCl pH 8.5 
20 mM HEPES 
1 mM DDT 
 
 
TAE Buffer 1 X 












Lysis buffer 2 
400 mM NaCl 
20 mM C2H7NO2, pH 5 
0.5 mM TCEP 
10 mM Imidazole 
5 % glycerol  
 
 
Wash buffer 2 
800 mM NaCl 
20 mM C2H7NO2, pH 5 
0.5 mM TCEP 
30 mM Imidazole 
5 % glycerol  
 
 
Elution buffer 2 
400 mM NaCl 
20 mM C2H7NO2. pH 5 
0.5 mM TCEP 
400 mM Imidazole 
5 % glycerol  
 
 
Gel filtration buffer 2 
50 mM NaCl 





Dialysis buffer 2 
20 mM NaF 




SDS running buffer 1 X 












Lysis buffer 3 
400 mM NaCl 
20 mM Tris, pH 8.5 
0.5 mM TCEP 
10 mM Imidazole 
5 % glycerol  
 
 
Wash buffer 3 
800 mM NaCl 
20 mM Tris, pH 8.5 
0.5 mM TCEP 
30 mM Imidazole 
5 % glycerol  
 
 
Elution buffer 3 
400 mM NaCl 
20 mM Tris, pH 8.5 
0.5 mM TCEP 
400 mM Imidazole 
5 % glycerol  
 
 
Gel filtration buffer 3 
150 mM NaCl 
20 mM phosphate buffer, 
pH 6.5 
0.5 mM TCEP 
5 % glycerol  
 
PBS buffer  
1 tablet of phosphate 
buffered saline dissolved 
in 200 mL dH2O, pH 7.4 
 
 
 
 
